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A B S T R A C T
Background
Acute postoperative pain is still an issue in patients undergoing abdominal surgery. Postoperative pain and side effects of analgesic
treatment, in particular those of opioids, need to be minimized. Opioid-sparing analgesics, possibly including dexmedetomidine, seem
a promising avenue by which to improve postoperative outcomes.
Objectives
Our primary aim was to determine the analgesic efficacy and opioid-sparing effect of perioperative dexmedetomidine for acute pain
after abdominal surgery in adults.
Secondary aims were to establish effects of dexmedetomidine on postoperative nausea and vomiting (PONV), gastrointestinal function
and mobilization, together with the side effect profile of dexmedetomidine.
Search methods
We searched the following databases: Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Institute for Scientific
Information (ISI), Web of Science and Cumulative Index to Nursing and Allied Health Literature (CINAHL), and reference lists of
articles to May 2014. We searched the Science Citation Index, ClinicalTrials.gov and Current Controlled Trials, and we contacted
pharmaceutical companies to identify unpublished and ongoing studies. We applied no language restrictions. We reran the search in
May 2015 and found nine studies of interest. We will deal with the studies of interest when we update the review.
Selection criteria
We included randomized, controlled trials of perioperative dexmedetomidine versus placebo or other drug during abdominal surgery
in adults. Trials included one of the following outcomes: amount of ’rescue’ opioid, postoperative pain, time to ’rescue’ analgesia,
participants requiring ’rescue’ analgesia, postoperative sedation, PONV, time to first passage of flatus and stool or time to first out-of-
bed mobilization.
1Perioperative dexmedetomidine for acute pain after abdominal surgery in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
Two review authors independently screened the titles and abstracts for eligibility. We retrieved full trial reports if necessary, and we
extracted relevant data from the included studies using a data collection form and assessed risk of bias. We resolved disagreements by
discussion with the third review author. We sought additional information of relevance for risk of bias assessment or extraction of data
by contacting study authors or, if necessary, co-authors from present or former studies.
Main results
Our systematic review included seven studies with a total of 492 participants. We included 422 participants in our analysis. Thirteen
studies are awaiting classification. For the comparison dexmedetomidine versus placebo (six studies, 402 participants), most studies
found a reduction in ’rescue’ opioid consumption in the first 24 hours after surgery, together with in general no clinically important
differences in postoperative pain (visual analogue scale (VAS) 0 to 100 mm, where 0 = no pain and 100 = worst imaginable pain) in the
first 24 hours after surgery - except for one study (80 participants) with a reduction in VAS pain at two hours after surgery in favour of
dexmedetomidine, with a mean difference of -30.00 mm (95% confidence interval (CI) -38.25 to -21.75). As the result of substantial
heterogeneity, pooling of data in statistical meta-analyses was not appropriate. The quality of evidence was very low for our primary
outcomes because of imprecision of results and risk of bias. Regarding our secondary aims, evidence was too scant in general to allow
robust conclusions, or the estimates too imprecise or of poor methodological quality. Regarding adverse effects, low quality data (one
study, 80 participants) suggest that the proportion of participants with hypotension requiring intervention was slightly higher in the
high-dose dexmedetomidine group with a risk ratio of 2.50 (95% CI 0.94 to 6.66), but lower doses of dexmedetomidine led to no
differences compared with control. Evidence for the comparison dexmedetomidine versus fentanyl was insufficient to permit robust
conclusions (one study, 20 participants).
Authors’ conclusions
Dexmedetomidine, when administered perioperatively for acute pain after abdominal surgery in adults, seemed to have some opioid-
sparing effect together with in general no important differences in postoperative pain when compared with placebo. However the
quality of the evidence was very low as the result of imprecision, methodological limitations and substantial heterogeneity among
the seven included studies. The clinical importance for patients is uncertain, in as much as the influence of dexmedetomidine on
patient-important outcomes such as gastrointestinal function, mobilization and adverse effects could not be satisfactorily determined.
All included studies were relatively small, and publication bias could not be ruled out. Applicability of evidence was limited to middle-
aged participants who were relatively free of co-morbidity and were undergoing elective abdominal surgery. A potential bias was a
considerable quantity of unobtainable data from studies with mixed surgery. To detect and investigate patient-important outcomes,
larger studies with longer periods of follow-up are needed.
P L A I N L A N G U A G E S U M M A R Y
Dexmedetomidine for prevention of acute pain after abdominal surgery in adults
Background and review question
Acute pain after surgery is a problem for patients undergoing abdominal surgery. In addition to postoperative pain, the side effects of
treatment with pain killers, in particular those of opioids (drugs resembling morphine), need to be reduced. Dexmedetomidine is an
opioid sparing drug (reduces the need for opioids). We reviewed the evidence about the effectiveness of dexmedetomidine in reducing
the need for opioids and in preventing acute pain after abdominal surgery in adults. We wanted to discover how safe dexmedetomidine
was and whether it was effective in preventing some of the known side effects of opioids, such as nausea and vomiting, reduced bowel
function and delayed mobilization (getting up and moving around) after abdominal surgery.
Study characteristics
Evidence is current to May 2014. We included seven studies with 492 participants from five different countries and included 422
participants in our analysis. Most participants were middle-aged. Participants had almost no diseases other than their reason for having
surgery. The type of surgery was planned abdominal surgery. Three of the seven studies looked only at obesity surgery. Participants
received dexmedetomidine right before or during their abdominal surgery. Six studies compared dexmedetomidine with no treatment,
and one small study compared dexmedetomidine with fentanyl (a strong opioid).
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We reran the search in May 2015 and found nine studies of interest, which we will discuss when we update the review. In total, 13
studies are awaiting classification.
Key results and quality of the evidence
Most of the studies that compared dexmedetomidine with no treatment found that dexmedetomidine reduced the need for opioids for
treating pain for 24 hours after surgery. During the same period, no important differences in pain were noted, except one study (80
participants) showed a reduction in intensity of pain at two hours after surgery with dexmedetomidine. The quality of the evidence
was very low because the results were not similar across studies, and because some studies were poorly conducted. The influence of
dexmedetomidine on postoperative nausea and vomiting could not be determined because results were not similar across studies. No
conclusion could be made for bowel function and mobilization and side effects such as postoperative sedation, as data were insufficient.
One studywith 80 participants reported a higher rate of low blood pressure (’low’meaning that medicationwas required) for participants
receiving a high dose of dexmedetomidine compared with no treatment, but for lower doses of dexmedetomidine, they noted no
differences compared with no treatment.
For the comparison dexmedetomidine versus fentanyl, data were insufficient to allow conclusions (only one small study).
Conclusion
Dexmedetomidine - compared with no treatment - seemed to reduce the need for opioids without worsening the experience of
postoperative pain after abdominal surgery in adults. However, the quality of evidence was very low because studies were poorly
conducted and because results were not similar across studies. The importance of these findings for patients was also uncertain because
the influence of dexmedetomidine on bowel function, mobilization and adverse effects could not be properly determined.The seven
included studies were small, so side effects associated with use of dexmedetomidine may be greater than this review reported. In addition,
we could not obtain relevant data from several studies because investigators mixed abdominal surgery with other types of surgery.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Dexmedetomidine for postoperative pain
Patient or population: adults having abdominal surgery
Setting: hospital
Intervention: perioperat ive dexmedetomidine
Comparison: dexmedetomidine vs placebo
Outcome Effecta Number of participants
(number of studies)
Quality of evidence
(GRADE)*
Comments
Amount of ’rescue’ opi-
oid (intravenous mor-
phine equivalents, mg)
24 hours af ter surgery
(MD, 95% CI)
Three of four stud-
ies found a reduct ion
in ’rescue’ opioid con-
sumption (Bakhamees
2007; Mohamed 2012;
Tufanogullari 2008).
One study showed re-
duced need for non-
opioid analgesia in
the dexmedetomidine
group and no dif ference
in consumption of ’res-
cue’ opioid (Park 2012,
42 part icipants)
259 (4 studies) ⊕©©©
very low
Downgraded 3 lev-
els because of seri-
ous risk of bias (
Mohamed 2012; Park
2012; Tufanogullari
2008), serious impreci-
sion of results (Park
2012; Tufanogullari
2008) and serious
inconsistency arising
f rom heterogeneity in
ef fect est imates
Postoperat ive
pain (VAS 0 to 100 mm,
visual analogue scale
f rom 0 = no pain to
100 = worst imaginable
pain) 24 hours af ter
surgery (MD, 95% CI)
No clinically important
dif f erence in VAS post-
operat ive pain
259 (4 studies) ⊕©©©
very low
Downgraded 3 levels
because of serious risk
of bias (Mohamed
2012; Park 2012;
Tufanogullari 2008),se-
rious imprecision and
serious inconsistency
arising f rom hetero-
geneity in amount of
’rescue’ analgesia be-
tween studies
Postoperat ive sedat ion
12 hours af ter surgery
(units of RSS, Ramsay
Sedation Scale f rom 1
= Anxious or agitated
or rest less to 6 = Unre-
sponsive) (MD, 95% CI)
Quantity of data was
too small to allow
a robust conclusion.
The only study report-
ing data found an in-
creased level of seda-
t ion with dexmedetomi-
dine, with a mean dif -
ference in RSS 1 to 6 of
1.60 units (95% CI 1.49
80 (1 study) ⊕©©©
very low
Downgraded 3 levels
because of serious risk
of bias and serious im-
precision (small quan-
t ity of data) (Xiao 2013)
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to 1.71) (Xiao 2013)
Postoperat ive nausea
and vomit ing (PONV)
(RR, 95% CI)
One study found re-
duced risk of PONV
with dexmedetomidine
(RR 0.54, 95% CI 0.33
to 0.87; Tufanogullari
2008, 77 part icipants)
and at the same
time reduced need for
ant iemetics. Two other
studies found risk ra-
t ios of PONV close
to favouring neither
dexmedetomidine nor
placebo (RR 0.67, 95%
CI 0.12 to 3.78 for
Bakhamees 2007, 80
part icipants) (RR 0.50,
95% CI 0.17 to 1.48 for
Mohamed 2012, 60 par-
t icipants)
217 (3 studies) ⊕⊕©©
low
Downgraded 2 levels
because of serious in-
consistency in outcome
def init ion (PONV sep-
arated in nausea and
vomit ing) (Bakhamees
2007; Mohamed
2012; Tufanogullari
2008) and risk of
bias (Bakhamees 2007;
Mohamed 2012)
Time to f irst passage of
f latus (hours, MD, 95%
CI)
Quantity of data was
too small to allow a
robust conclusion. The
only study report ing
data found no dif fer-
ence in t ime to f irst
passage of f latus (
Tufanogullari 2008)
77 (1 study) ⊕⊕©©
low
Downgraded 2 levels
because of very seri-
ous imprecision (small
quant ity of data)
Time to f irst passage of
stool (hours, MD, 95%
CI)
NR NR
Time to f irst out-of -bed
mobilizat ion (hours,
MD, 95% CI)
Quantity of data was
too small to allow a
robust conclusion. The
only study report ing
data found no dif fer-
ence in t ime to f irst
out-of -bed mobilizat ion
(Tufanogullari 2008)
77 (1 study) ⊕⊕©©
low
Downgraded 2 levels
because of very seri-
ous imprecision (small
quant ity of data)
M D: mean dif ference; CI: conf idence interval; RR: risk rat io; NR: no data reported
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* GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and
may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is
likely to change the est imate
Very low quality: We are very uncertain about the est imate
aPerform ing meta-analyses was not appropriate for any outcome. All studies had a relat ively small number of part icipants
and substant ial heterogeneity for three main reasons:
1. Methodological lim itat ions in several studies (high or unclear risk of bias)
2. Clinical variat ion with great dif f erence in amount of ’rescue’ analgesia, type of surgery, body mass index, route and t im ing
of administrat ion of dexmedetomidine and anaesthet ic agents, etc
3. Stat ist ical variat ion with relat ively great imprecision in results and a high I2 stat ist ic for several outcomes
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
B A C K G R O U N D
Description of the condition
Acute postoperative pain is still an issue in patients undergoing
abdominal surgery. Inefficient relief of pain may be associated
with reduced mobility, postoperative complications and prolon-
gation of hospital stay (Kehlet 2003). Although different analgesic
agents and techniques are available, opioids remain one of the
cornerstones of postoperative pain treatment because of their ex-
cellent analgesic properties. Nevertheless, opioids have worrisome
side effects such as nausea, vomiting, gastrointestinal dysfunction,
drowsiness, urinary retention and respiratory depression. These
adverse effects may sometimes outweigh analgesic benefits, as they
may impair postoperative rehabilitation as well (Bonnet 2007).
The gastrointestinal side effects of opioids are particularly unde-
sirable after abdominal surgery, which in itself is associated with
paralytic ileus. It has been recommended to use opioids after ab-
dominal surgery only when non-opioid drugs provide insufficient
analgesia (Kehlet 2003). Consequently, there is a need to develop
and extend the use of non-opioid analgesia for acute pain after
abdominal surgery.
Description of the intervention
Dexmedetomidine is an alpha-2 adrenoceptor agonist with seda-
tive, analgesic, sympatholytic and anxiolytic properties. Indica-
tions for use are presently limited to sedation in intensive care
units (ICUs) (Dexdor product information; Precedex prescribing
information) and sedation in surgical patients who are not intu-
bated (Precedex prescribing information). A recent clinical prac-
tice guideline suggests dexmedetomidine for the treatment of delir-
ium in the ICU (Barr 2013). Dexmedetomidine is presently li-
censed for intravenous use only, but othermodes of administration
are being explored, including intramuscular, epidural, intra-artic-
ular, buccal and intranasal routes (Chan 2010). The most com-
mon adverse effects of dexmedetomidine are hypotension, brady-
cardia, hypertension and nausea; less common adverse effects in-
clude atrial fibrillation, fever and dry mouth, and cases of sinus
arrest have been reported (Dexdor product information; Precedex
prescribing information). Infusion of dexmedetomidine exceed-
ing 24 hours is not recommended because of risk of agitation and
respiratory failure (Precedex prescribing information); this precau-
tion is not stated in Dexdor product information. The same drug
dexmedetomidine is sold as Precedex and Dexdor under two dif-
ferent regulatory authorities.
How the intervention might work
The analgesic properties of dexmedetomidine probably involve
both peripheral and central mechanisms. Centrally, the antinoci-
ceptive effect seems to be related to stimulation of alpha-2 adreno-
ceptors located both at the spinal level in neurons of the dorsal
horn and at a supraspinal level in the locus coeruleus. The periph-
eral analgesic mechanism is not entirely elucidated (Chan 2010).
Dexmedetomidine is eight times more selective of alpha-2 adreno-
ceptors than clonidine; thus it is expected to be a more effective
analgesic agent (Chan 2010).
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Several trials have demonstrated a significant opioid-sparing ef-
fect of dexmedetomidine (Arain 2004; Gurbet 2006; Lin 2009;
Unlugenc 2005; Vandermeulen 2006). A great benefit is that
dexmedetomidine does not seem to compromise respiratory func-
tion (Mantz 2011; Villela 2003). Other possible benefits include
neuroprotection (attenuation of delirium) and cardioprotection
(prevention of myocardiac ischaemia), although these have not
been convincingly demonstrated (Biccard 2008; Chrysostomou
2008; Mantz 2011; Wijeysundera 2009).
Why it is important to do this review
To improve postoperative outcomes after abdominal surgery, both
postoperative pain and side effects of analgesic treatment, in par-
ticular those of opioids, must be minimized. The physiological
mechanisms of postoperative pain operate at several different lev-
els; thus multi-modal or balanced analgesia is generally recom-
mended (Kehlet 2003). In abdominal surgery, the opioid side ef-
fects are particularly undesirable. As side effects increase at higher
doses (Bonnet 2007;Marret 2005), opioid-sparing analgesics seem
a promising avenue by which postoperative outcomes can be im-
proved. In this context, it is appropriate to examine critically the
risks and benefits of dexmedetomidine.
As a result of its opioid-sparing effect, it is plausible that patients
treated with dexmedetomidine after abdominal surgery will expe-
rience better gastrointestinal function (less nausea and vomiting
and shorter duration of paralytic ileus). Thus, there is reason to
believe that the use of dexmedetomidine is associated with fewer
postoperative complications and facilitates recovery after abdom-
inal surgery. This assumption needs to be investigated, as it has
been shown that greater analgesic efficacy does not automatically
translate into improved clinical postoperative outcomes such as
recovery of bowel function, active mobilization and fewer organ-
related complications (Liu 2007; White 2010). Moreover, studies
differ as to whether postoperative recovery is facilitated by the use
of dexmedetomidine (Tan 2010; Unlugenc 2005).
Another question that needs to be addressed is whether the anal-
gesic efficacy of dexmedetomidine comes at the cost of problem-
atic side effects, in particular, postoperative sedation and cardio-
vascular side effects including bradycardia and hypotension (Arain
2004; Biccard 2008; Lin 2009; Tan 2010). With regards to post-
operative nausea and vomiting (PONV), some studies show that
dexmedetomidine has a lower incidence of nausea compared with
opioids (Lin 2009).Other studies show that dexmedetomidine has
no effect on the incidence of opioid-induced bowel dysfunction
despite its opioid-sparing properties (Vandermeulen 2006).
Therefore, this systematic review is needed in order to clarify the
analgesic properties of dexmedetomidine when used periopera-
tively in abdominal surgery, as well as to establish the harms and
benefits associated with its use.
O B J E C T I V E S
Our primary aim was to determine the analgesic efficacy and opi-
oid-sparing effect of perioperative dexmedetomidine for acute pain
after abdominal surgery in adults.
Secondary aims were to establish effects of dexmedetomidine on
PONV, gastrointestinal function and mobilization, together with
the side effect profile of dexmedetomidine.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs) evaluating the
effect of dexmedetomidine for acute pain after abdominal surgery
in adults, irrespective of language and publication status. We
would have included cluster-randomized trials and factorial trials
(in a factorial trial, at least two intervention comparisons are car-
ried out simultaneously), had we identified any.
We excluded cross-over trials, quasi-randomized trials and all non-
randomized trials.
Types of participants
We included adult participants undergoing all types of abdominal
surgery, including both open and laparoscopic procedures. We
included general and regional forms of anaesthesia. We defined
abdominal surgery as surgery to intra-abdominal organs, excluding
gynaecological, urological, vascular and superficial surgery (such
as hernia repair).
Types of interventions
We compared perioperative (preoperative, intraoperative or post-
operative) administration of dexmedetomidine with other treat-
ments or placebo (with ’rescue’ medication). We included all
modes of administration and all variations of dosage, frequency
and duration.
We included interventions combining dexmedetomidine with an-
other treatment if that same treatment, without dexmedetomi-
dine, was given to the control group. We also included interven-
tions combining dexmedetomidine with another treatment if the
design of the trial was factorial, and if we did not suspect any in-
teraction between treatments.
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Types of outcome measures
Primary outcomes
• The opioid-sparing effect of dexmedetomidine - measured
by amount of ’rescue’ opioid, administered via any route, at
three, six, 12 and 24 hours after end of surgery.
• The analgesic efficacy of dexmedetomidine - measured at
rest and on movement, as defined by study authors, by visual
analogue scale (VAS) 0 to 100 mm, where 0 mm corresponds to
no pain and 100 mm corresponds to worst imaginable pain. Use
of a VAS scale 0 to 10 cm was converted to VAS 0 to 100 mm.
We regarded any use of verbal or numerical rating scales (NRSs)
from 0 to 10 as convertible with VAS. We selected the measuring
time points of three, six, 12 and 24 hours after end of surgery.
Secondary outcomes
• Time to first request of ’rescue’ analgesia.
• Proportion of participants needing ’rescue’ analgesia.
• Postoperative sedation - assessed by clinical measures at
three, six and 12 hours after end of surgery. By ’clinical
measures’, we understood values estimated by observer or
participant, such as the Ramsey Sedation Scale (RSS), and not by
use of technology, such as the bispectral index (BIS).
• Proportion of participants with PONV until 24 hours after
end of surgery, or proportion of participants treated with
antiemetics.
• Time to first passage of flatus after end of surgery or
proportion of participants with delay to first passage of flatus.
• Time to first passage of stool after end of surgery or
proportion of participants with delay to first passage of stool.
• Time to first out-of-bed mobilization after end of surgery or
proportion of participants with delay to first out-of-bed
mobilization.
• Post-interventional complications or adverse effects,
particularly hypotension, bradycardia, delirium and respiratory
failure, reported as a proportion of participants.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases: Cochrane Cen-
tral Register of Controlled Trials (CENTRAL; 2014, Issue 5;
see Appendix 1); MEDLINE, Ovid SP (1956 to May 2014;
see Appendix 2); EMBASE, Ovid SP (1982 to May 2014; see
Appendix 3); Institute for Scientific Information (ISI) Web of Sci-
ence (1950 to May 2014; see Appendix 4) and Cumulative In-
dex to Nursing and Allied Health Literature (CINAHL) via EB-
SCO host (1980 to May 2014; see Appendix 5). When searching
the databases, we used both subject headings and free-text terms.
We combined our subject search terms with the Cochrane highly
sensitive search strategy for identifying RCTs, as suggested in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We adapted our MEDLINE search strategy when search-
ing all other databases.
We searched the references in accepted studies for additional eli-
gible trials.
We reran the search in May 2015.
We applied no language restrictions.
Searching other resources
We searched the references in accepted studies for additional eli-
gible trials.
We searched the Science Citation Index, ClinicalTrials.gov and
Current Controlled Trials in August 2014 to identify additional
published, unpublished and ongoing studies.
Furthermore, we contacted the medical companies responsible for
marketing of dexmedetomidine, to ask about additional and un-
published research.
Data collection and analysis
Selection of studies
Two review authors (LJL, HKN) independently examined the ti-
tles and abstracts obtained by the above searches. We excluded
trials that did not meet all of the eligibility criteria referred to on
the data collection form (Appendix 6). If a decision could not be
made on the basis of the abstract alone, we retrieved the full trial
report. We documented the reason for exclusion of trials when the
reason for exclusion was not obvious.
We resolved disagreements between the two review authors by
consulting with a third review author (AMM).
If a trial report provided insufficient information for a decision on
inclusion, we contacted the first author of the trial.
We (LJL, HKN) were not blinded to reference details during the
selection process.
Data extraction and management
Two review authors (LJL, HKN) went through the full text of all
included trials. We independently completed the data collection
form (Appendix 6) in the process of extracting data.
Both review authors (LJL, HKN) performed a pilot test of the
data collection form.
We resolved disagreements by discussion, and if they remained
unresolved, by consulting with a third review author (AMM).
Whendisagreements remained,we contacted the first author of the
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relevant trial to seek further information. If we could not resolve
a disagreement, we reported this in our review.
Assessment of risk of bias in included studies
Two review authors (LJL,HKN) independently assessed the risk of
bias for each eligible trial.We resolved disagreements by discussion
with a third review author (AMM).
Weperformed the assessment of risk of bias as recommended in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).
We assessed the risk of bias by evaluating the following seven do-
mains in each trial: random sequence generation, allocation con-
cealment, blinding of participants and personnel, blinding of out-
come assessment, incomplete outcome data, selective reporting
and other bias. On the basis of the description of the study’s ap-
proach to each domain (including relevant quotes and our com-
ments), wemade a judgement of high, lowor unclear risk of bias for
each domain, using the specific criteria recommended by Higgins
2011.
We originally planned to include studies in our meta-analysis re-
gardless of our assessment of risk of bias for an outcome as high, low
or unclear. Subsequently, and if data were sufficient, we planned
to perform sensitivity analyses, first by excluding studies with high
risk of bias for the outcome in question, and second by exclud-
ing studies with high and unclear risk of bias. However, no meta-
analyses were appropriate.
Measures of treatment effect
For dichotomous outcomes, we chose risk ratio (RR) as the pre-
ferred effectmeasure. If relevant, we planned to calculate the num-
ber needed to treat for an additional beneficial outcome (NNTB)
and the number needed to treat for an additional harmful out-
come (NNTH), although we did not intend to incorporate these
into the meta-analyses.
For continuous outcomes, we calculated the difference inmeans or
the mean difference (MD) when measurement scales were similar.
If measurement scales were not similar, we planned to use the
standardized mean difference (SMD).
We treated ordinal outcomes and measurement scales as continu-
ous data.
Unit of analysis issues
To avoid making a unit of analysis error, we would be particularly
cautious when facing a trial that did not follow a ’standard’ design,
meaning one measurement for each outcome for each participant
in a double-arm trial. The two following cases need to be men-
tioned specifically.
• For any study with multiple treatment arms, we tried to
combine groups to create a single comparison. But if the
combination of groups was not meaningful, we judged the
relevance of all treatment groups for our review question. If one
or several treatment arms were not relevant, we excluded these
from the analysis, although we mentioned them under
Characteristics of included studies and evaluated whether the
exclusion introduced any risk of bias. If all treatment arms were
relevant to our review question, we planned to perform a
multiple treatments meta-analysis (MTM).
• For any study that provided multiple observations for the
same outcome, we performed a separate analysis for each relevant
observation, expecting this to be the case for several of our
selected outcomes: amount of ’rescue’ opioid (at three, six, 12
and 24 hours after surgery), postoperative pain at rest and on
movement (at three, six, 12 and 24 hours after surgery) and
postoperative sedation (at three, six and 12 hours after surgery).
Dealing with missing data
For any type of missing data, we contacted the first author of the
relevant trial to ask for additional information. If the contact in-
formation was not directly available, we tried to retrieve an email
address or a postal address by searching the Internet, or by contact-
ing co-authors from present or former studies. Some attempted
correspondence may not have reached the addressee.
When we encountered missing data, we planned to perform an
intention-to-treat (ITT) analysis if possible. If an ITT analysis was
not possible, we based our analysis on available data and discussed
risk of bias and the potential impact of missing data. In any meta-
analyses, we planned to perform a sensitivity analysis for missing
data concerning best-case and worst-case scenarios.
Assessment of heterogeneity
We considered heterogeneity arising from clinical diversity (related
to participants, interventions and outcomes) and from method-
ological diversity (related to risk of bias) to be present a priori. We
quantified statistical heterogeneity by using the I2 statistic, which
reflects the percentage of variability that is due to heterogeneity
rather than to random error.
We planned to perform meta-analyses. A meta-analysis would be
appropriate, though, only if variation in results was not consider-
able, as judged by clinical andmethodological measures and by the
statistical measure of heterogeneity, the I2 statistic, which ideally
but not necessarily should be below 75% (Higgins 2011). Addi-
tionally, a meta-analysis would be appropriate only if the amount
of information was sufficient (size and number of trials) (Higgins
2011).
Assessment of reporting biases
Weplanned to detect publication bias (forming part of small-study
effects) by creating funnel plots for our primary outcomes. As fewer
than 10 studies were included in this review (seven included), we
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were not able to create a funnel plot. (See Differences between
protocol and review for themethodswewill apply if future updates
of this review include enough studies to permit use of a funnel
plot.)
Data synthesis
As mentioned in the Assessment of heterogeneity section, we
planned to perform a meta-analysis if heterogeneity was not con-
siderable. However, because of either a small number of studies or
considerable heterogeneity, we performed no meta-analyses. (See
Differences between protocol and review for themethods that will
be applied if future updates of this review permit meta-analyses.)
Among our selected outcomes, we did not expect post-interven-
tional complications and adverse effects to be suitable for a meta-
analysis or for inclusion in the ’Summary of findings’ table. In-
stead, we intended to prepare a narrative report.
Subgroup analysis and investigation of heterogeneity
Wewere not able to perform subgroup analyses, as no meta-analy-
ses were appropriate. SeeDifferences between protocol and review.
Sensitivity analysis
We were not able to perform sensitivity analyses, as no meta-
analyses were appropriate. See Differences between protocol and
review.
Summary of findings
We used the principles of the GRADE (Grades of Recommenda-
tion, Assessment, Development and Evaluation) system (Guyatt
2008) in our review to assess the quality of the body of evidence
associated with specific outcomes (amount of ’rescue’ opioid, post-
operative pain, postoperative sedation, PONV, time to first pas-
sage of flatus, time to first passage of stool, time to first out-of-
bed mobilization) and to construct a ’Summary of findings’ table,
if possible using GRADE software. The GRADE approach ap-
praises the quality of a body of evidence according to the extent to
which confidence indicates that an estimate of effect or association
reflects the item being assessed. The quality of a body of evidence
considers within-study risk of bias (methodological quality), di-
rectness of the evidence, heterogeneity of the data, precision of
effect estimates and risk of publication bias.
R E S U L T S
Description of studies
Results of the search
Our systematic search of databases revealed 2137 records, which
amounted to 1883 records when duplicates were removed. By
searching other resources, we identified one potentially rele-
vant record from a reference list in the article by Yacout 2012
(Lawrence 1997), and we found six ongoing studies by search-
ing ClinicalTrials.gov, Science Citation Index and Current Con-
trolled Trials (Awad 2014; Jung 2014; Kim 2014; Wai 2014; Yoo
2014; Zeeni 2014). Of the 1890 potentially relevant records, we
excluded 1783 records as not pertinent upon screening titles and
abstracts. We screened 101 full-text articles and excluded 49 for
obvious reasons. Of the 58 remaining studies, we excluded 32 for
specific reasons mentioned for each study under Characteristics
of excluded studies and listed these in groups in the study flow
diagram (Figure 1). Of the remaining 26 studies, we could not
classify 13 because we needed additional information from study
authors (Altindis 2008; Anvaroglu 2008; Arain 2004; Bicer 2006;
Ceballos 2011; Kilicaslan 2006; Kordan 2006; Mizrak 2010;
Scheinin 1992; Subasi 2012; Unlugenc 2005; Yacout 2012; Yektas
2011; see Characteristics of studies awaiting classification), and we
found that six were ongoing studies (see Characteristics of ongoing
studies). This process resulted in inclusion of seven studies in the
narrative synthesis and revealed none for inclusion in a quantita-
tive synthesis (meta-analysis).
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Figure 1. Study flow diagram
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We reran the search in May 2015. We found 250 records and
identified nine new studies of interest. We listed the nine studies
of interest under Studies awaiting classification and in Table 1,
and we will incorporate them into formal review findings during
the review update.
Included studies
We included seven studies in this review (Bakhamees 2007; Feld
2006; Khanduja 2013;Mohamed 2012; Park 2012; Tufanogullari
2008; Xiao 2013). The total number of participants was 492, and
sample sizes ranged from 20 to 120 participants. After we ex-
cluded some intervention arms, our analysis included 422 partic-
ipants,and sample sizes from the seven studies ranged from 20 to
80 participants.
Design
All seven studies were randomized controlled trials with paral-
lel groups. Three trials had multiple arms: One study comprised
three arms with different dosages of dexmedetomidine compared
with a fourth placebo arm (Tufanogullari 2008); for our sta-
tistical analysis, we pooled the three dexmedetomidine groups.
Another study compared dexmedetomidine with dexmedetomi-
dine-fentanyl and control (Mohamed 2012). To avoid a potential
synergy of different medical interventions, we chose to exclude
the dexmedetomidine-fentanyl arm. The third study (Xiao 2013)
compared a dexmedetomidine plus high-dose remifentanil group
versus a placeboplus high-dose remifentanil group versus a placebo
plus low-dose remifentanil group. For this study, we excluded the
latter arm to meet our eligibility criteria, with dexmedetomidine
as the sole difference between groups. We included no factorial
trials and no cross-over trials. All studies were single-centre stud-
ies. See Characteristics of included studies and Table 2 for addi-
tional details. These tables describe the actual design of the study,
regardless of our decisions to exclude or pool intervention groups.
Participants
The review analysis included 422 participants. At least 254 were
women (60.2%) and 148 men (35.1%); for the last 20 partici-
pants, we noted an error in reported data (see Table 2; Bakhamees
2007). Studies were conducted in Egypt (two studies, 140 partici-
pants; Bakhamees 2007;Mohamed 2012); USA (two studies, 100
participants; Feld 2006; Tufanogullari 2008); India (one study, 60
participants; Khanduja 2013); Korea (one study, 42 participants;
Park 2012); and China (one study, 80 participants; Xiao 2013).
Participants’ mean age ranged from 29 to 58 years with an upper
limit of 66 years of age and no exact report of lower limit (inclusion
criteria from 18 years of age). Types of surgery included bariatric
surgery (two studies with 100 participants having a gastric by-
pass and one study with 80 participants having gastric banding or
gastric bypass; Bakhamees 2007; Feld 2006; Tufanogullari 2008);
cholecystectomy (two studies, 102 participants; Khanduja 2013;
Park 2012); and major abdominal cancer surgery (one study, 60
participants; Mohamed 2012). Four studies (Bakhamees 2007;
Khanduja 2013; Park 2012; Tufanogullari 2008) included laparo-
scopic surgery (262 participants); two included open surgery (100
participants) (Feld 2006, Xiao 2013); and one study reported no
details about type of surgery, other than that it was major ab-
dominal cancer surgery (60 participants; Mohamed 2012). Stud-
ies included participants with American Society of Anesthesiolo-
gists Physical Status (ASA) I to III (the three studies with bariatric
surgery included participants with ASA II to III, and the other
studies included participants with ASA I to II). All studies includ-
ing ASA II to III defined exclusion criteria comprising neurolog-
ical, cardiovascular, respiratory, renal and hepatic disease. Other
common exclusion criteria were alcohol and drug abuse and psy-
chiatric disease.
See Characteristics of included studies and Table 2 for additional
details.
Interventions
Six of the seven studies compareddexmedetomidine versus placebo
or control (Bakhamees 2007; Khanduja 2013; Mohamed 2012;
Park 2012; Tufanogullari 2008; Xiao 2013). One study (20 partic-
ipants) compared dexmedetomidine with fentanyl (Feld 2006). In
five of seven studies (Bakhamees 2007; Feld 2006;Khanduja 2013;
Park 2012; Tufanogullari 2008), dexmedetomidine was adminis-
tered intravenously as an infusion intraoperatively (three studies
initiated the infusion by a bolus; Bakhamees 2007; Feld 2006;
Park 2012), in another study, solely as an intravenous bolus before
induction of anaesthesia (Xiao 2013) and in another study (60 par-
ticipants), as a bolus intrathecally before induction of anaesthesia
(Mohamed 2012). Dosage for the intravenous bolus ranged from
0.5 µg/kg to 1.0 µg/kg. The intrathecally administered bolus was
a dosage of 5 µg. Dosage of intravenous infusion ranged from 0.4
to 0.6 µg/kg/h, except for the study which included three dose
regimens of 0.2, 0.4 and 0.8µg/kg/h (Tufanogullari 2008), which
were pooled to a single intervention group in our analysis.
See Characteristics of included studies and Table 2 for details.
The table describes the actual interventions provided in the study,
regardless of our decisions to exclude or pool intervention groups.
Outcomes
See Characteristics of included studies and Table 2 for additional
details. The table describes only the outcomes relevant for our re-
view. All studies reported other outcomes, and some studies had
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several primary outcomes not reported in this review. In the fol-
lowing paragraphs, we will present a resume of the characteristics
of our primary and secondary outcomes.
Primary outcomes
Six out of seven studies contributed to our primary outcomes
(Bakhamees 2007; Feld 2006; Mohamed 2012; Park 2012;
Tufanogullari 2008; Xiao 2013). Time points selected for our pri-
mary outcomes showed variability as reported by included studies.
We decided post hoc, but before looking further into the actual
results, that variation of one, two, three and six hours was accept-
able for our prespecified time points, respectively, three, six, 12
and 24 hours postoperatively. One study reported ’postoperative
day one’ instead of 24 hours (Tufanogullari 2008), and two stud-
ies reported the amount of ’rescue’ opioid and VAS pain at two
hours after surgery instead of at three hours (Bakhamees 2007;
Feld 2006). We have reported these data without adjustments.
Concerning the opioid-sparing effect of dexmedetomidine or the
amount of ’rescue’ opioid, four studies reported monotherapy
analgesic regimens consisting of PCA (patient-controlled analge-
sia) morphine (Bakhamees 2007; Feld 2006), intravenous mor-
phine with no further specification (Xiao 2013) and intravenous
tramadol (Mohamed 2012). Two studies had three-step ’rescue’
analgesia regimens; one consisted of intravenous fentanyl, intra-
venous PCA morphine and oral hydromorphone-acetaminophen
(Tufanogullari 2008), and the other consisted of oral ketorolac,
intravenous tramadol and intravenous fentanyl (Park 2012). We
converted all types of opioid to the equianalgesic intravenous dose
of morphine on the basis of the following equivalents, when ap-
proximately:
• 1 mg intravenous morphine equals
• 21 mg intravenous tramadol (30 mg oral tramadol) equals
• 0.02 mg (20 µg) intravenous fentanyl equals
• 0.75 mg oral hydromorphone
(emedicine.medscape.com; globalrph.com; healthquality.va.gov;
irf.dk; en.wikipedia.org/wiki/equianalgesic; tramadolfacts.com).
If a study used paracetamol or a non-steroidal anti-inflammatory
drug (NSAID), we did not include these data in our analysis but
presented themonly in a narrative report.One study reported only
the total dose of intraoperative and postoperative pentazocine;
we reported this information narratively as well, along with the
outcome of proportion of participants needing ’rescue’ analgesia
(Khanduja 2013).
Concerning the analgesic efficacy of dexmedetomidine measured
on a visual analogue scale (VAS) for pain, one study used a verbal
rating scale (VRS 0 to 10) (Tufanogullari 2008), and the other used
a VAS. Two studies used median and interquartile range (IQR)
(Bakhamees 2007; Feld 2006), which we converted to mean and
standard deviation (SD), making the assumption that the distri-
bution of VAS is symmetrical and similar to a normal distribution.
The median was thus directly used as a mean, and the IQR was
assumed to be equal to an SD of 1.35 (chapter 7.7.5.3. Higgins
2011). One study reported VAS pain at two and four hours after
surgery instead of at three hours, and we chose to report the mean
of these two time points.
Secondary outcomes
Five studies contributed to our secondary outcomes, of which
one reported time to first request of ’rescue’ analgesia (Mohamed
2012); two reported proportion of participants needing ’res-
cue’ analgesia (Khanduja 2013; Tufanogullari 2008); one re-
ported postoperative sedation 12 hours after surgery measured by
the Ramsay Sedation Scale (Xiao 2013); three reported PONV
(Bakhamees 2007; Mohamed 2012; Tufanogullari 2008); one re-
ported time to first passage of flatus (Tufanogullari 2008) and one
reported time to first out-of-bed mobilization (reported as time
to ambulation by study authors; Tufanogullari 2008). Mohamed
2012 reported postoperative sedation with no time point specified
and nothing else other than ’no significance between groups’. No
studies reported time to first passage of stool.
Concerning the proportion of participants with PONV, all three
studies with this outcome divided PONV into participants
with nausea and participants with vomiting (Bakhamees 2007;
Mohamed 2012; Tufanogullari 2008). We chose to report only
on participants with nausea and excluded those with vomiting to
avoid making a unit of analysis error. One study (Tufanogullari
2008) reported number of participants needing ’rescue’ antiemetic
therapy, as well as nausea scores (verbal rating scale 0 to 10), during
the first hour postoperatively. We presented this additional infor-
mation narratively.
Excluded studies
We excluded 32 studies for specific reasons mentioned under
Characteristics of excluded studies. This table comprises the stud-
ies that might appear to meet eligibility criteria but were excluded
after a closer look at the full-text article. (For details of the reasons
for exclusion by group, see Figure 1.)
We excluded studies without a control group. Akinci 2011 exem-
plified this, including three intervention groups with dexmedeto-
midine but no control group.
We excluded studies in which dexmedetomidine was not the sole
difference between intervention groups, or in which dexmedeto-
midine was not compared with another single drug, to avoid any
synergy between dexmedetomidine and another drug.Málek 2010
and Marangoni 2005 exemplified this.
We excluded studies with procedures such as hernia repair, gy-
naecological surgery, urological surgery, procedures to the kidneys
and vascular surgery. We planned to include surgery to the spleen
in our review; however no studies examined this type of procedure
(except one study awaiting classification; Unlugenc 2005). Gupta
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2014b provided mixed surgery, including plastic and otorhino-
laryngological surgery, but also regional ’general surgery’ of about
one hour duration. We contacted the study authors by email to
confirm which type, but we received no reply. We excluded this
study because it probably did not examine abdominal surgery.
We excluded studies with outcomes relevant to our review if no
reports described outcomes at the specific time points prespecified
in our protocol (Jessen 2013) - with particular variance (one, two,
three and six hours of variance for three, six, 12 and 24 hours,
respectively). Harsoor 2014 exemplified this.
Studies awaiting classification
Thirteen studies are awaiting classification because we needed ad-
ditional information from study authors,and we have had no suc-
cess when attempting to correspond. (SeeCharacteristics of studies
awaiting classification for further details.)
We would have included Ceballos 2011 in our review, but because
VAS postoperative pain was reported as a dichotomous value (’no
pain’ = VAS 0 to 4, ’pain’ = VAS 5 to 10) and actually measured
values were not included, we categorized this study as awaiting
classification. Study authors did not report type or amount of ’res-
cue’ analgesia. We contacted these authors to request the appro-
priate data, and if and when they reply, we will include this study
in the next updated version of this review. This study also reported
postoperative sedation, but not at or near a time point prespecified
by our review.
Yacout 2012 reported VAS pain as a mean with no variance at
all (no standard deviation, P value or other). We contacted study
authors without success. We could have imputed a variance, but
we chose to let the study be described as unclassified, because a
statistical analysis of VAS pain for this study would be problematic
at any rate as the ’rescue’ analgesia used was not an opioid but
was ketorolac. An NSAID is not directly convertible to opioid;
therefore this study did not contribute to a statistical analysis for
our other main outcome, the opioid-sparing effect of dexmedeto-
midine, and our two main outcomes cannot be interpreted to our
satisfaction one without the other.
Unlugenc 2005 included mixed surgery, including mini-laparo-
tomy, cholecystectomy, splenectomy and inguinal, incisional or
umbilical hernia repair. We contacted study authors to request in-
dividual participant data for the three groups that did not undergo
hernia repair, but without success. The same problem applied
to five other studies (Arain 2004; Bicer 2006; Kilicaslan 2006;
Mizrak 2010; Scheinin 1992) for which we also contacted first
authors without success. One other study looked at lower abdom-
inal surgery without further definition (both men and women in-
cluded), and we contacted the first study author for details, with-
out success (Altindis 2008).
Four studies could not be classified because we could not retrieve
the full text, and our attempts to contact study authors were un-
successful (Anvaroglu 2008; Kordan 2006; Subasi 2012; Yektas
2011).
Ongoing studies
We identified six ongoing studies. See Characteristics of ongoing
studies for details.
Awad 2014 (recruiting participants) compares three different doses
of dexmedetomidine with the primary outcomes of shivering and
quality of emergence from anaesthesia. This study might not be
relevant for this review as no outcomes and time points seem
to correspond directly to ours. The same applies to Jung 2014,
which compared anaesthesia with (1) sevoflurane, (2) propofol
and remifentanil, (3) sevoflurane and dexmedetomidine and (4)
propofol, remifentanil and dexmedetomidine. Jung et al did not
specify outcomes relevant for this review, other than ’safety’, which
we presume translates to complications or adverse effects. The type
of surgery is not specified as other than abdominal surgery. Kim
2014 is investigating the effect of dexmedetomidine in combina-
tion with fentanyl on pain after surgery for colon cancer. This
study is registered as completed and has not been verified since
March 2012. We await results from this study. Wai 2014 is in-
vestigating the effect of morphine and COX-2 inhibitor with or
without dexmedetomidine on pain after colorectal cancer surgery.
These trial authors did not specify time points for assessment of
postoperative pain, but given that follow-up is five days, they prob-
ably will report values for one or more time points relevant to this
review. They also report on flatus, which is a relevant outcome
for our review that has been assessed by few studies. Yoo 2014
is investigating the effect of dexmedetomidine on gastrointestinal
function after laparoscopic gastrectomy due to gastric cancer. They
have been recruiting participants since June 2014. Zeeni 2014 is
also investigating dexmedetomidine for analgesia after bariatric
surgery (laparoscopic sleeve gastrectomy). This study has several
outcomes relevant to this Cochrane review, and it is currently re-
cruiting participants (starting in August 2014); we await study
results.
Risk of bias in included studies
For a detailed argumentation for each study’s risk of bias, please
see the risk of bias tables under Characteristics of included studies.
For an overview of the risk of bias for all domains and outcomes
and for all studies, please see Figure 2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
16Perioperative dexmedetomidine for acute pain after abdominal surgery in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Please note that the yellow colour in the figures, signifying ’unclear
risk of bias’, does not permit a distinction between ’not relevant’
and ’not sufficient information’.
Allocation
Assessment of risk of selection bias consists of a judgement of
how the random sequence was generated and how the allocation
was concealed from participants and from investigators enrolling
participants.
Three out of seven studies used a computer-generated random
sequence or random number table and were judged to have low
risk of bias (Feld 2006; Tufanogullari 2008; Xiao 2013), whereas
the remaining four studies presented insufficient information to
enable us to make a judgement. Concerning allocation conceal-
ment, only one study provided enough information to allow us to
make a judgement, which indicated low risk of bias (Tufanogullari
2008).
See Characteristics of included studies for additional details.
Blinding
One study was convincingly double-blinded and described details
of how this was done (Tufanogullari 2008); therefore we assigned
this study as having low risk of bias for all outcomes.
Two studies included a non-blinded anaesthesiologist but blinded
participants with blinding of some of the personnel assessing out-
comes (Bakhamees 2007; Feld 2006). A non-blinded anaesthesiol-
ogist might lead to a difference in the administration of anaesthet-
ics, but for one study, such a difference would lead to an under-
estimation of effect (Bakhamees 2007), and for the other study, it
probably would not influence effects on pain and ’rescue’ analgesia
postoperatively (Feld 2006). Therefore, both studies had low risk
of bias concerning pain and ’rescue’ analgesia. When it comes to
post-interventional complications and side effects, a non-blinded
anaesthesiologist caused high risk of bias for the complications
reported in one study (Feld 2006), whereas the other study re-
ported no complications (Bakhamees 2007). See Characteristics
of included studies for additional details.
One study was single-blinded and reported no further details,
probably including blinded participants and a non-blinded anaes-
thesiologist. As the time of follow-up was about 30 minutes post-
operatively, it was probably the anaesthesiologist who assessed all
postoperative outcomes. The non-blinded anaesthesiologist might
have had an influence on the measured difference in amount of
analgesia given intraoperatively, but as this would lead to an under-
estimation of effect, risk of bias was low concerning postoperative
pain and ’rescue’ analgesia (Khanduja 2013). See Characteristics
of included studies for additional details. Three studies did not
provide enough information about blinding to enable us to make
a clear judgement (Mohamed 2012; Park 2012; Xiao 2013).
Incomplete outcome data
All studies had low risk of bias concerning incomplete outcome
data. Only Tufanogullari 2008 had excluded participants from
the final analysis - one in each of the three dose-differentiated
dexmedetomidine intervention groups. Exclusion was result of
surgical reasons in all three cases; therefore, we have judged risk of
bias as low.
See Characteristics of included studies for additional details.
Selective reporting
For one of the seven included trials, we found a published proto-
col (Tufanogullari 2008). However, this study had unclear risk of
selective reporting because outcomes prespecified in the protocol
were described in very general terms only. Two outcomes seemed
to be added post hoc (number of participants discharged on post-
operative day one and number of days until discharge), but they
were secondary outcomes and showed no significant differences
between groups; therefore, risk of bias was not judged as high.
Only one study had low risk of selective reporting bias (Bakhamees
2007). Even though the protocol was not available, outcomes de-
scribed in the study’s Methods section and outcomes reported in
the study’s Results section corresponded.
The remaining studies had unclear (Khanduja 2013; Xiao 2013)
or high risk of selective reporting bias (Feld 2006; Mohamed
2012; Park 2012) because information was insufficient to enable
us to make a judgement, or because substantial irregularities were
apparent between what was prespecified in the Methods section
and what was actually reported in the Results section.
See Characteristics of included studies for additional details.
Other potential sources of bias
Two studies were judged as having high risk of other bias.
Mohamed 2012 had remarkably low standard deviations for the
amount of ’rescue’ opioid (see Analysis 1.6), making detailed in-
formation important about differences in anaesthetic agents be-
tween groups and other analgesic drugs used. Furthermore, the
study provided no details about which type of surgery was per-
formed, other than that it was major abdominal cancer surgery.
We attempted, without success, to contact the first author of this
study.
We judged Tufanogullari 2008 as having high risk of other bias be-
cause criteria for the use of the three-step ’rescue’ analgesia regimen
were not clearly described. Furthermore, investigators did not de-
scribe the information given to participants on how to administer
the analgesia at home. Therefore, one might suspect that the study
lacked control of participant compliance at home, leading to po-
tential contamination of outcomes. This study was sponsored in
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part by a medical company that manufactured dexmedetomidine,
but it was unclear if this relationship introduced other potential
bias. We contacted the first study author to request further infor-
mation, without success.
For three studies, informationwas insufficient to enable us tomake
a clear judgement (Khanduja 2013; Park 2012; Xiao 2013). Two
studies seemed to have no other apparent bias (Bakhamees 2007;
Feld 2006). Only Tufanogullari 2008 reported a potential conflict
of interest.
See Characteristics of included studies for additional details.
Effects of interventions
See: Summary of findings for the main comparison
Six (Bakhamees 2007; Khanduja 2013; Mohamed 2012; Park
2012; Tufanogullari 2008; Xiao 2013) of the seven included stud-
ies compared dexmedetomidine with placebo, whereas one study
compared dexmedetomidine with fentanyl (Feld 2006).
See Summary of findings for the main comparison, Data and
analyses and Table 3 for additional details.
Comparison 1. Dexmedetomidine versus placebo
For all outcomes in this comparison, we considered performing
meta-analyses unsuitable. For our main outcomes at 24 hours af-
ter surgery, the quantity of data seemed sufficient to be pooled.
However, for the amount of ’rescue’ opioid, heterogeneity was con-
sidered substantial clinically and statistically (I2 statistic = 98%);
therefore a meta-analysis was inappropriate (for additional details
about clinical and methodological heterogeneity between studies,
see Quality of the evidence). For the outcome of postoperative
pain 24 hours after surgery, four studies (Mohamed 2012; Park
2012; Tufanogullari 2008; Xiao 2013) reported data, and statis-
tical heterogeneity was not substantial (I2 statistic = 0%). Never-
theless, we considered a meta-analysis to be inappropriate for this
outcome because we judged clinical heterogeneity to be substan-
tial. We made this judgement mainly for two reasons.
• When heterogeneity was considered substantial for the
outcome of amount of ’rescue’ analgesia, it seemed reasonable to
regard VAS postoperative pain as equally heterogeneous (the
studies were almost the same at 24 hours after surgery).
• The standard deviation reported for the study with highest
statistical weight seemed clinically unrealistic (Mohamed 2012).
For the proportion of participants with PONV, we considered a
meta-analysis inappropriate because a relatively small quantity of
data was combined with imprecision in collection of results. For
all other outcomes, the quantity of data was too sparse to permit
meta-analyses.
Five studies (Bakhamees 2007; Mohamed 2012; Park 2012;
Tufanogullari 2008; Xiao 2013) reported data for our two pri-
mary outcomes, although not for all time points, and five studies (
Bakhamees 2007; Khanduja 2013;Mohamed 2012; Tufanogullari
2008; Xiao 2013) contributed to some of our secondary outcomes.
One study (Khanduja 2013) reported only one outcome collected
by us: the proportion of participants needing ’rescue’ analgesia -
a secondary outcome that we had not prespecified to be included
in the Summary of findings for the main comparison.
Primary outcomes
The opioid-sparing effect of dexmedetomidine (amount of
’rescue’ opioid)
At three hours after surgery, we found low-quality evidence that
intravenous morphine equivalent consumption was reduced with
dexmedetomidine, with a mean difference of -5.20 mg (95% con-
fidence interval (CI) -5.79 to -4.61) for Bakhamees 2007 (80 par-
ticipants) and -3.65 mg (95% CI -6.04 to -1.26) for Tufanogullari
2008 (77 participants) - respectively, 51% and 39% reduction. I
2 statistic = 34%. See Analysis 1.1. We downgraded the quality
of evidence by two levels because of some study limitations and
imprecision (small quantity of data).
No studies reported data for the time points six and 12 hours after
surgery.
At the time point 24 hours after surgery, we found very low-quality
evidence that intravenous morphine equivalent consumption was
reduced with dexmedetomidine, with a mean difference of -12.00
mg (95% CI -15.10 to -8.90) - a 25% reduction - for Bakhamees
2007 (80 participants); -7.20 mg (95%CI -7.48 to -6.92) - a 54%
reduction - for Mohamed 2012 (60 participants); and -56.00 mg
(95% CI -112.01 to 0.01) - a 26% reduction - for Tufanogullari
2008 (77 participants). One study, Park 2012 (42 participants),
was more difficult to quantify; investigators provided a three-step
analgesia regimen, with a significant difference in the need for ke-
torolac (first step) favouring dexmedetomidine (intravenous ke-
torolac, mg, mean difference (MD) -22.50, 95% CI -41.10 to -
3.90), no significant difference in the need for tramadol (second
step) (converted to intravenous morphine, mg, MD 0.10, 95%CI
-0.95 to 1.15) and no significant difference in the number of par-
ticipants requiring fentanyl (third step) (risk ratio (RR) 0.18, 95%
CI 0.01 to 4.02) (see Analysis 1.2). We downgraded the quality of
evidence by three levels, from high to very low, because of serious
study limitations, heterogeneity (I2 statistic = 98%) and impreci-
sion of results (broad statistical variance).
Estimated effects should be evaluated together with VAS postop-
erative pain; all of the above-mentioned studies reported reduced
intensity of pain with dexmedetomidine or no significant differ-
ence compared with placebo (at varying time points). See the sec-
tion below.
The analgesic efficacy of dexmedetomidine (VAS
postoperative pain)
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At three hours after surgery, we found very low-quality evidence
for a reduction in VAS postoperative pain (0 to 100 mm) with
dexmedetomidine, with a mean difference of -30.00 mm (95%
CI -38.25 to -21.75) for Bakhamees 2007 (80 participants), and
a clinically unimportant mean difference of -2.00 mm (95% CI -
3.29 to -0.71) for Mohamed 2012 (60 participants). See Analysis
1.3.We downgraded the quality of evidence by three levels because
of serious study limitations, imprecision (small amount of data)
and heterogeneity of results (I2 statistic = 98%).
At six hours after surgery, we found very low-quality evidence for
clinically unimportantmean differences inVAS postoperative pain
for two studies (a slight reduction of -3.00 mm (95% CI -5.95
to -0.05) with dexmedetomidine for Mohamed 2012 (60 partic-
ipants), and a mean difference of -2.00 mm (95% CI -11.02 to
7.02) for Park 2012 (42 participants) favouring neither group). I2
statistic = 0%. See Analysis 1.4.We assessed the quality of evidence
as very low because of serious study limitations and imprecision
(small quantity of data).
At 12 hours after surgery, results were much the same as for VAS
postoperative pain at six hours after surgery, with very low-quality
evidence for mean differences of less clinical importance from two
studies (a modest reduction of -6.00 mm (95% CI -6.72 to -5.28)
with dexmedetomidine forMohamed 2012 (60 participants), and
a mean difference of -2.00 mm (95% CI -6.61 to 2.61) for Xiao
2013 (80participants) favouringneither group). I2 statistic = 65%.
See Analysis 1.5. We downgraded the quality of evidence for the
same reasons.
At 24 hours after surgery, the quantity of data was larger than for
the other time points, but the quality was equally very low for
evidence of mean differences in VAS pain close to favouring nei-
ther dexmedetomidine nor placebo (-7.00 mm (95% CI -19.40
to 5.40) for Park 2012 (42 participants), 3.00 (95% CI -12.28 to
18.28) for Tufanogullari 2008 (77 participants), 0.00 (95% CI -
3.94 to 3.94) for Xiao 2013 (80 participants) and -2.00 (95% CI
-2.80 to -1.20) for Mohamed 2012 (60 participants)). I2 statis-
tic = 0%. See Analysis 1.6. The quality of evidence was down-
graded by three levels because of serious study limitations, but also
for the same reasons (heterogeneity and imprecision) that led to
downgrading of quality of the evidence for the amount of ’rescue’
analgesia at 24 hours after surgery (given that the two outcomes
are closely interrelated and that studies reporting data at 24 hours
after surgery were almost the same).
Asmentioned, postoperative pain effect estimates should be evalu-
ated together with the amount of ’rescue’ analgesia, and all studies
reporting VAS postoperative pain also reported amount of ’rescue’
analgesia to be reduced with dexmedetomidine compared with
placebo (see the section above). However, the amount of ’rescue’
analgesia for Xiao 2013 was reported only at 48 hours after surgery
and therefore was not reported by us, but study authors’ report of
VAS postoperative pain at 12 and 24 hours should be interpreted
together with the information that the study found a reduction in
amount of ’rescue’ morphine at 48 hours after surgery in favour
of dexmedetomidine, with a mean difference of -21.00 mg (95%
CI -29.46 to -12.54).
Secondary outcomes
Regarding time to first request of ‘rescue’ analgesia, we assessed
the quality of evidence as very low for the increase in time found
for dexmedetomidine, with a mean difference of 3.07 hours (95%
CI 2.76 to 3.38) (Mohamed 2012, 60 participants). The quality
of evidence was downgraded because of serious study limitations
and imprecision of results (small quantity of data).
For the proportion of participants needing ‘rescue’ analgesia, we
found very low quality of evidence for effect estimates of this out-
come. In one study (Khanduja 2013, 60 participants), follow-up
was very short after end of surgery (probably around 30 minutes);
we did not consider this sufficient to conclude how many partici-
pants needed ’rescue’ analgesia. However, had the study evaluated
the time to need for ’rescue’ analgesia, one might imagine that a
significant effect could be found in favour of dexmedetomidine,
particularly because the dexmedetomidine group received a signif-
icantly larger amount of intraoperative analgesia than the placebo
group, thus underestimating the reported effect estimate (RR0.44,
95% CI 0.15 to 1.29) in favour of dexmedetomidine for the out-
come proportion of participants needing ’rescue’ analgesia. The
other study reporting data (Tufanogullari 2008, 77 participants)
found that all participants without exception needed ’rescue’ anal-
gesia (with seven days of follow-up); therefore we did not consider
this study to be suitable for an evaluation of this outcome either,
because apparently, the type of surgery and the type of anaesthesia
in all circumstances would create a need for postoperative ’rescue’
analgesia.
Regarding postoperative sedation, data were reported only at 12
hours after surgery, and we found very low-quality evidence of an
increased level of sedation with dexmedetomidine, with a mean
difference in Ramsay Sedation Scale (RSS) 1 to 6 of 1.60 units
(95% CI 1.49 to 1.71) (Xiao 2013, 80 participants). Reasons for
downgrading one level were study limitations and imprecision of
results (small quantity of data).
For the number of participants with PONV, we found low-quality
evidence of reduced risk with dexmedetomidine in one study (RR
0.54, 95% CI 0.33 to 0.87) for Tufanogullari 2008 (77 partic-
ipants) and risk ratios in two studies close to favouring neither
dexmedetomidine nor placebo (RR 0.67, 95% CI 0.12 to 3.78
for Bakhamees 2007 (80 participants); RR 0.50, 95% CI 0.17
to 1.48 for Mohamed 2012 (60 participants)). I2 statistic = 0%.
See Analysis 1.7. The quality of evidence was downgraded by two
levels because of study limitations and imprecision in reporting of
results,as all three studies reported nausea and vomiting as separate
outcomes, with the risk that some participants counted double
with pooling of outcomes to PONV (unit of analysis error), or that
cases were underreported if only nausea was reported as PONV.
The study that found reduced risk of PONV with dexmedetomi-
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dine also found reduced need for ’rescue’ antiemetics at the first
postoperative day (RR 0.35, 95% CI 0.20 to 0.60) together with
slightly reduced intensity of nausea on a verbal rating scale (VRS)
of 0 to 10 compared with placebo during the first 30 minutes
postoperatively (Tufanogullari 2008, 77 participants).
For time to first passage of flatus (no data for stool), low-quality
evidence suggested a mean difference close to favouring neither
dexmedetomidine nor placebo, with reduction in time for the
placebo group of 5.00 hours (95% CI -5.60 to 15.60) compared
with dexmedetomidine, found in the only study reporting data
(Tufanogullari 2008, 77 participants). Downgrading of two levels
was imposed because of imprecision (small quantity of data).
Regarding time to first out-of-bed mobilization, low-quality evi-
dence suggested amean difference in favour of neither dexmedeto-
midine nor placebo, with a mean difference of -0.33 hours after
surgery (95% CI -3.95 to 3.29) for Tufanogullari 2008 (77 par-
ticipants). Quality of evidence was again downgraded because of
imprecision (small quantity of data).
Concerning post-interventional complications or adverse effects,
Tufanogullari 2008 (80 participants) reported the number of par-
ticipantswith hypotension requiring intervention (phenylephrine)
other than a decrease in anaesthetic agents and a 200 mL fluid
bolus, including two participants (10%) in the dexmedetomidine
(DEX) 0.2 group, four (20%) in theDEX 0.4 group and 10 (50%)
in the DEX 0.8 group, with the latter showing a risk ratio of 2.50
(95%CI 0.94 to 6.66) compared with the control group with four
out of 20 (20%) participants. Tufanogullari 2008 also reported
that the number of participants with hypertension and/or tachy-
cardia requiring intervention (labetalol) other than an increase in
anaesthetic agents (desflurane) was three (15%) in the DEX 0.2
group, one (5%) in the DEX 0.4 group and zero out of 20 (0%)
in the DEX 0.8 group, with the latter showing a risk ratio of 0.09
(95% CI 0.01 to 1.54) compared with the control group with five
out of 20 participants (25%). No other studies within this com-
parison reported side effects not already accounted for. The quality
of evidence for these side effects was considered low, with down-
grading by two levels due to imprecision of results. A slight ten-
dency toward a probable dose-response gradient may be present,
but because of imprecision of results we have not upgraded the
quality of evidence. See Characteristics of included studies.
Comparison 2. Dexmedetomidine versus fentanyl
Only one study reported data for this comparison (Feld 2006, 20
participants). Because of this small quantity of data, we did not
present this comparison in our ’Summary of findings’ table.
For our primary outcomes, the study reported data for the time
point two hours after surgery, which we have accepted as a tol-
erable variation from our time point of three hours after surgery.
For the amount of ’rescue’ analgesia, consumption of intravenous
morphine was reduced with dexmedetomidine, with a mean dif-
ference of -8.50 mg (95% CI -12.75 to -4.25). For VAS postop-
erative pain, intensity was reduced with dexmedetomidine, with
a mean difference of -40.00 mm (95% CI -51.53 to -28.47). The
quality of evidence for these estimates was considered low and was
downgraded by two levels because of imprecision (small quantity
of data).
For our secondary outcomes, investigators provided data only
for post-interventional complications/side effects. This study re-
ported the number of participants with hypotension requiring in-
tervention (epinephrine) as three out of 10 in the dexmedetomi-
dine group versus one out of 10 in the fentanyl group (RR 3.00,
95% CI 0.37 to 24.17). Another complication reported was pro-
longed mechanical ventilation in one out of 10 participants in the
fentanyl group versus null in the dexmedetomidine group (RR
0.33, 95% CI 0.02 to 7.32). We considered the quality of evi-
dence for these outcomes as very low, downgraded by three levels
because of high risk of bias pertaining to an unblinded anaesthe-
siologist (see Characteristics of included studies) and because of
imprecision (small quantity of data).
D I S C U S S I O N
Summary of main results
See Summary of findings for the main comparison, Table 2 and
Table 3 for details.
Our systematic review included seven studies with a total popula-
tion of 492 participants, and we included 422 participants in our
analysis.
Comparison 1. Dexmedetomidine versus placebo
Six studies (402 participants; Bakhamees 2007; Khanduja 2013;
Mohamed 2012; Park 2012; Tufanogullari 2008; Xiao 2013) com-
pared dexmedetomidine with placebo.Most studies reporting data
found a reduction in ’rescue’ opioid consumption both at three
hours after surgery (Bakhamees 2007; Tufanogullari 2008) and at
24 hours after surgery (Bakhamees 2007; Mohamed 2012; Park
2012; Tufanogullari 2008), together with in general no differ-
ence in visual analogue scale (VAS) postoperative pain, and the
only study (Bakhamees 2007, 80 participants) with an important
difference in VAS postoperative pain found a reduction at two
hours after surgery in favour of dexmedetomidine. As the result
of substantial statistical and clinical heterogeneity, meta-analyses
were not appropriate, and the quality of evidence was very low
according to the GRADE (Grades of Recommendation, Assess-
ment, Development and Evaluation) system for our twomain out-
comes (although low at three hours after surgery for amount of
’rescue’ analgesia). Regarding our secondary outcomes,the quan-
tity of data was too small, or the estimates too imprecise or of
too poor methodological quality, to enable us to reach any robust
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conclusions. Regarding post-interventional complications or side
effects, data of low-quality evidence from one study (Tufanogullari
2008, 80 participants) showed that the number of participants
with hypotension requiring intervention was slightly higher in a
high-dose dexmedetomidine group (0.8 µg/kg/h) with a risk ratio
of 2.50 (95% confidence interval (CI) 0.94 to 6.66), but groups
with lower doses of dexmedetomidine showed no difference com-
pared with control groups.
Comparison 2. Dexmedetomidine versus fentanyl
For the comparison dexmedetomidine versus fentanyl, only one
small study (Feld 2006, 20 participants) reported data and found
a reduction in both ’rescue’ opioid consumption and VAS postop-
erative pain with dexmedetomidine, but follow-up was only two
hours after surgery, and the amount of evidence must be consid-
ered too small to permit a conclusion. No data for our secondary
outcomes were reported for this comparison, except for some post-
interventional adverse effects that were too rare and too biased
to allow a conclusion regarding differences between groups (need
for prolonged mechanical ventilation and hypotension requiring
intervention).
No studies compared dexmedetomidine with interventions other
than fentanyl or control.
Overall completeness and applicability of
evidence
The included studies covered a population not entirely applica-
ble to and representative of the typical population one meets in
a hospital setting. The total range of age was limited to 18 to 66
years, and means of age ranged from 29 to 58 years, thus leav-
ing the effect of dexmedetomidine on the older population unin-
vestigated. Regarding health status, the population represented in
the included studies overall was relatively free of co-morbidity. All
studies including American Society of Anesthesiologists Physical
Status (ASA) III specifically excluded neurological, cardiovascular,
respiratory, renal and hepatic disease. Cultures/countries were re-
stricted to Asia, Egypt and USA. The type of surgery was exclu-
sively elective and showed a preponderance of bariatric surgery,
but also included cholecystectomy, abdominal cancer surgery and
unspecified abdominal surgery; laparoscopic (≥ 262 participants)
and open procedures (≥ 100 participants) were represented.
The interventions explored by included studies consisted of varied
dosages and modes of administration (bolus, infusion or both).
Studies showed a preponderance of intravenous administration
(six studies, 362 participants) compared with other routes (in-
trathecally in one study with 60 participants).
Outcomes explored by the included studies in general were suf-
ficiently defined and externally applicable, although some valu-
able details were warranted. For VAS pain, no studies specified
whether it occurred at rest or at movement, and only two studies
made explicit after what criteria ’rescue’ analgesia were adminis-
tered (Mohamed 2012 at VAS pain ≥ 3, Park 2012 at VAS pain
> 4). Tufanogullari 2008 described criteria for the use of patient-
controlled analgesia (PCA) morphine, but not for the other two
steps in the three-step ’rescue’ analgesia regimen. Many outcomes
of importance for patients were not adequately represented by the
included studies, particularly outcomes requiring a longer period
of follow-up.
Quality of the evidence
For an overview of quality of evidence, see Summary of findings
for the main comparison.
According to the GRADE working group (Guyatt 2008; Higgins
2011), we downgraded the quality of evidence according to an
evaluation of methodological limitations (internal risk of bias),
indirectness of evidence, heterogeneity/inconsistency of results,
imprecision of results and publication bias. We upgraded quality
of evidence according to any large magnitude of effect, a probable
underestimation of effect or a dose-response gradient. Please note
that external validity/applicability is not part of the quality of
evidence assessment.
• We foundmethodological limitation to be serious for one
study (Mohamed 2012). Not only was the risk of selective
reporting high as well as the risk of other bias, the precision of
results was so accurate, with remarkably small standard
deviations, that a far more detailed description of study methods
was particularly required. Two other studies (Park 2012;
Tufanogullari 2008) had some, less serious, methodological
limitations. For more detailed information about internal risk of
bias/study limitations, see Figure 2, Figure 3 and Characteristics
of included studies.
• Regarding indirectness of evidence, we found none among
populations, interventions, comparisons nor outcomes. We did
not regard bariatric surgery with an obese population (for three
out of seven studies) as causing indirectness of evidence, but
merely as providing a reason for heterogeneity in results.
• Heterogeneity between studies for amount of ’rescue’
analgesia after 24 hours was substantial both statistically and
clinically. The amount of ’rescue’ analgesia seemed very large for
Tufanogullari 2008, whereas it seemed surprisingly small for
Park 2012 and Mohamed 2012. Possible explanations may
include differences in types of surgery and anaesthetic agents;
different dosages, timing and route of administration for
dexmedetomidine; differences in body mass index of participants
and criteria for and mode of administering ’rescue’ analgesia
(VAS pain ≥ 3 or > 4, frequency of VAS pain evaluation, self
administration or administration by personnel), together with
differences in the definition of time point noted at 24 hours after
surgery or at ’postoperative day one’ (which may include up to
several additional hours).
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• Imprecision of results was substantial for Tufanogullari 2008,
in particular, considering the large standard deviation for the
amount of ’rescue’ analgesia; Park 2012 also had considerable
imprecision. All studies had a relatively small number of
participants. For postoperative nausea and vomiting (PONV),
imprecision of results was due to a divergent definition of PONV
(all studies reported nausea and vomiting as separate outcomes;
therefore, if PONV was reported as one outcome in this review, a
unit of analysis error or an underreporting of cases would be
committed).
• Regarding risk of publication bias, it is difficult to make a
proper assessment on this topic because a funnel plot was not
considered appropriate. Only one study (Tufanogullari 2008)
reported that it was funded in part by a manufacturer of
dexmedetomidine, but we did not assess this study as having
high risk of bias (see Characteristics of included studies). Studies
were all relatively small; therefore a small-study effect leading to
overestimation of effects cannot be ruled out. However, we did
not downgrade the quality of evidence but only reported the risk
narratively. Please note that publication bias pertaining to
outcomes (selective reporting bias) has been evaluated under
internal risk of bias (see also Characteristics of included studies).
Consequently, we downgraded the quality of evidence for our
two main outcomes by three levels, to very low quality of ev-
idence, signifying that “we are very uncertain about the esti-
mate” (Guyatt 2008). This downgrading was done because of
serious study limitations (Mohamed 2012), some study limita-
tions (Park 2012; Tufanogullari 2008), imprecision of results (Park
2012; Tufanogullari 2008) and heterogeneity in effect estimates
(Mohamed 2012; Park 2012; Tufanogullari 2008).
Potential biases in the review process
A major problem for this review that may have introduced risk
of bias was the great quantity of data that could not be obtained.
Six additional studies met the inclusion criteria, except that the
type of surgery was mixed with other than abdominal procedures.
The number of participants from these studies who underwent
an abdominal procedure was at least 87 and was probably around
100. We contacted authors of all of these studies to request in-
dividual participant data, without luck (Arain 2004; Bicer 2006;
Kilicaslan 2006; Mizrak 2010; Scheinin 1992; Unlugenc 2005).
What added to the risk of bias were the studies for which full text
could not be retrieved, or for which additional data were needed,
that might have met our eligibility criteria. We contacted study
authors without luck, or we found that a contact address was not
retrievable (Altindis 2008; Anvaroglu 2008; Kordan 2006; Subasi
2012; Yektas 2011). If study authors get back to us at a later stage,
we will include the data in future updates of this review.
Another point of potential dispute was that some studies were
excluded even though they came close to meeting our eligibility
criteria. We had prespecified some time points for some outcomes
and were faced with a decision to include or exclude studies with
variation in these time points. We made an arbitrary and post
hoc decision about how much variation we would permit. An
alternative would have been to have no prespecified time points
and then combine post hoc what was presented - a choice also
not without risk of bias. Among both excluded studies (Harsoor
2014) and included studies, data were not provided for some out-
comes (e.g. sedation assessed immediately after surgery (Mohamed
2012), amount of ’rescue’ analgesia reported only after 48 hours
(Xiao 2013)). Our decision about permissible variation in time
points was made before we analysed data properly, thereby reduc-
ing risk of bias.
For the outcome of proportion of participants with PONV,
three studies reporting data separated PONV into two outcomes
(Bakhamees 2007; Mohamed 2012; Tufanogullari 2008). We
would have to choose to add the data and risk a unit of analysis
error (participants having both nausea and vomiting would count
double) or to collect only data for nausea, thereby risking underre-
porting of the incidence of PONV.We tried to obtain information
about whether participants with vomiting also were registered as
having nausea, without reply. Anticipating that this probably was
the case, we chose to report only data for nausea as PONV. We
could have chosen to change our outcome so that ’PONV’ would
become ’nausea’, but as this would be a post hoc decision and
as PONV is a generally accepted outcome, this decision was not
tempting, although it would have made our reporting precise.
Our decision to use the GRADE system for evaluation of quality
of evidence (Guyatt 2008) was made primarily to follow the con-
sensus to apply this tool in Cochrane reviews. However, for this re-
view in which meta-analyses were not performed, one could point
to a weakness by applying this evaluation tool. Speaking of ’low
quality of the evidence’ and translating it into ’further research is
very likely to have an important impact on our confidence in the
estimate of effect and is likely to change the estimate’ seems to
presume that one pooled and quantifiable estimate can be found.
Therefore, for outcomes for which results of studies cannot be
pooled in a meta-analysis, the terminology of the GRADE system
may be less than optimal. Our decision to report GRADE Work-
ing Group grades of evidence for an outcome if only one study is
reporting data can also be discussed because the GRADE system
seems to draw its strength primarily as an evaluation tool across
studies, inasmuch as the criteria for downgrading the quality of
evidence include heterogeneity between studies and publication
bias - criteria that cannot be applied unless several studies present
data for a particular outcome. Furthermore, when looking at our
Summary of findings for the main comparison, one may find it
contra-intuitive that some of our outcomes, for which the quan-
tity of data was small, have been downgraded by only two levels,
whereas other outcomes with a larger quantity of available data
have been downgraded by three levels (depending on other quali-
tative reasons for downgrading). In other terms, the GRADE sys-
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tem does not distinguish between quantity of evidence and qual-
ity of evidence but rather incorporates them into one judgement.
The GRADE system does not seem to incorporate the possibility
of making an ’upper limit’ to quality level of evidence when the
quantity of data is small. For reviews with scant data, this may
result in contra-intuitive conclusions of the following nature: ’We
found low quality evidence for inconclusive evidence’.
For other potential minor biases in the review process, see also
Table 4.
Agreements and disagreements with other
studies or reviews
Two recent systematic reviews on the topic, both of which inves-
tigate a broader range of surgical procedures, found results much
in accordance with the results of our review.
One systematic review (Schnabel 2013) including 28 random-
ized controlled trials with 1420 participants investigated the anal-
gesic efficacy and safety of intraoperative dexmedetomidine ver-
sus placebo or opioids in adults undergoing surgery (major or mi-
nor surgery, comprising gynaecology, ear-nose-throat, urology, or-
thopaedics, neurosurgery, abdominal surgery, heart surgery). The
median quality score of data reporting was 5 (range 1 to 7) on a
modified 7-point Oxford scale. This meta-analysis also looked at
the same primary outcomes as this review, at time points of one,
two, four, 24 and 48 hours after surgery. Meta-analyses for these
outcomeswere appropriate only for the comparison of dexmedeto-
midine versus placebo. Postoperative pain (numerical rating scale
(NRS) 0 to 10) was significantly reduced in the dexmedetomidine
group versus the placebo group (including nine studies and 492
participants) at all time points, with a maximum mean difference
of -1.59 (95% CI -2.37 to -0.8) at one hour after surgery, showing
diminishing differences with time, with a minimum mean dif-
ference of -0.41 (-0.53 to -0.29) at 48 hours after surgery. Post-
operative morphine consumption (including 10 studies with 528
participants) was significantly reduced in the dexmedetomidine
group compared with the placebo group, with mean differences
increasing from -3.79 mg (95% CI -5.36 to -2.23) to -17.24 mg
(95% CI -24.38 to -10.10) to -39.22 mg (95% CI -47.52 to -
30.91) at time points two, 24 and 48 hours after surgery. We
found a non-significant reduction in the remaining time points at
one and four hours after surgery. Heterogeneity was substantial (I2
statistic > 90%), however, for most of the time points for both out-
comes. We performed several subgroup analyses, including anal-
yses for different types of surgery, and found that for abdominal
surgery, the reduction in NRS pain was smaller than for other
types of surgery, whereas the significant reduction in morphine
consumption was not significantly different compared with other
surgical procedures. Regarding secondary outcomes, participants
treated with dexmedetomidine had a non-significant reduction in
risk ratio for PONV at most time points. The review also found
a significant reduction in pruritus for dexmedetomidine treated
groups, but for other opioid-related side effects, such as urinary
retention and respiratory depression, data were insufficient. Intra-
operative bradycardia requiring intervention (e.g. atropine) was
significantly greater in participants treated with dexmedetomidine
than for those given placebo (risk ratio (RR) 2.66, 95%CI 1.54 to
4.58), whereas for intraoperative hypotension, the risk ratio was
not significantly higher in the dexmedetomidine treated groups
(RR 1.85, 95% CI 0.83 to 4.13).
The other systematic review and meta-analysis (Blaudszun 2012)
investigated randomized trials conducted to test any systemic al-
pha-2 agonist (vs placebo or no treatment) administered periop-
eratively to adults undergoing non-cardiac surgery under general
anaesthesia. Inclusion criteria consisted of reported data on post-
operative cumulative opioid consumption or pain intensity. Re-
view authors included 30 studies with 1792 participants, in which
clonidine (19 studies) or dexmedetomidine (11 studies) was com-
pared with placebo (no head-to-head comparison of clonidine
and dexmedetomidine). Types of surgery included abdominal (14
studies), hysterectomy (five), spine (four), ear-nose-throat (one),
orthopaedic (one), vascular (one) and not specified (four). The
median quality score was 4 (range 2 to 7) on a modified 7-point
Oxford scale. This review found a morphine-sparing effect at 24
hours after surgery (four studies, 419 participants) with a mean
difference of -14.5 mg (95% CI -22.1 to -6.8) for dexmedetomi-
dine (which was greater than for clonidine at -4.1 mg (95% CI -
6.0 to-2.2), although heterogeneity was considerable (I2 statistic =
91%). For VAS postoperative pain (0 to 10 cm) at 24 hours after
surgery (three studies, 225 participants), a significant reduction
in mean difference (-0.6 cm, 95% CI -0.9 to -0.2; I2 statistic =
33%) favoured dexmedetomidine versus placebo (approximately
the same for clonidine). At 48 hours after surgery, both alpha-2 ag-
onists had lost their analgesic effects. The incidence of early nausea
was decreased with both drugs compared with control. Only three
studies reported haemodynamic side effects for dexmedetomidine,
showing increased risk of postoperative bradycardia, whereas the
quantity of reported data about adverse effects for clonidine was
larger and showed increased risk of intraoperative and postopera-
tive hypotension. The review authors suspected a possible element
of selective reporting in the dexmedetomidine trials concerning
haemodynamic adverse effects.
It is worth mentioning the results of two of the studies awaiting
classification, for which the main portion of participants under-
went abdominal surgery. Both trials were included in the two re-
views mentioned above. The first study (Unlugenc 2005) found
results much in accordance with the results of our review, whereas
the other study (Arain 2004) found an opioid-sparing effect of
dexmedetomidine only during the first few hours after surgery.
Unlugenc 2005, a Turkish randomized controlled trial, investi-
gated the analgesic effect of dexmedetomidine for 60 adults (18 to
64 years of age) undergoing abdominal surgery (mini-laparotomy
(three); cholecystectomy (30); splenectomy (four); inguinal, inci-
sional or umbilical hernia repair (23)) who were classified as ASA I
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to II and were treated with an intravenous bolus of dexmedetomi-
dine 1 µg/kg or placebo at 10 minutes before induction of anaes-
thesia. This study found a significant reduction in ’rescue’ mor-
phine consumption in favour of dexmedetomidine at time points
six, 12 and 24 hours after surgery. At 24 hours after surgery, the
dexmedetomidine group had received a median of PCAmorphine
(mg) of 23.8 (range 69.5) versus a median of 44 (range 52) in the
placebo group (P value < 0.01) - a 28% reduction. Review authors
reported no significant differences between groups in VAS pain at
rest. The study found no significant differences between groups
for sedation score (5 point scale), nausea score (number of partic-
ipants with nausea not reported), time to extubation nor time to
recovery. Opioid-induced side effects (urinary retention or pruri-
tus) were very few and showed no significant differences between
groups. See Characteristics of studies awaiting classification. We
would evaluate risk of bias for this study as low for all domains.
The other study, Arain 2004, a randomized controlled trial from
USA, investigated the effect of dexmedetomidine (bolus 1 µg/
kg and infusion 0.4 µg/kg/h, initiated 30 minutes before end of
surgery) versus morphine in 34 adults (ASA I to III, mean age
60 years) undergoing intra-abdominal (15), major orthopaedic
(13) and other surgery (six). The study found no difference in
the use of PCA morphine (based on frequent increments and no
total) during 24 hours after stay in the post-anaesthesia care unit
(PACU), but a significant difference in the total amount of ’rescue’
morphine administered by a nurse in the PACU (precise length of
stay not reported) favouring dexmedetomidine (mean difference
-4.50 mg, 95% CI -5.41 to -3.59), together with a significant
reduction in the number of participants needing ’rescue’ analge-
sia during the first 60 minutes after surgery (RR 0.07, 95% CI
0.01 to 0.43). This study found no significant differences between
groups for VAS postoperative pain, sedation or nausea (follow-up
for these outcomes was only 100 minutes after surgery). Investi-
gators reported no cardiovascular or respiratory complications re-
quiring intervention (heart rate in PACUwas significantly lower in
the dexmedetomidine group; mean arterial blood pressure showed
no significant differences between groups, except for a small and
transient increase in mean arterial blood pressure after bolus of
dexmedetomidine). We evaluated the study to have low risk of
bias in most domains and no high risk of bias. See Characteristics
of studies awaiting classification for additional details.
When we look at randomized trials (including reviews of ran-
domized trials), side effects and complications (or protection from
these) associated with the use of dexmedetomidine are difficult to
detect, typically because they are underpowered. A large systematic
review and meta-analysis (Lin 2012) investigated the safety and
sedative effects of dexmedetomidine compared with placebo or
another sedative agent in elective cardiac surgery patients, with ad-
ministration of dexmedetomidine that was not perioperative but
was provided for postoperative sedation for at least six hours. This
review also included studies other than randomized controlled tri-
als (retrospective and prospective cohort studies), and the num-
ber of participants amounted to 16,818 (11 studies). The review
found that dexmedetomidine was associated with shorter length
of mechanical ventilation and lower risk of delirium, ventricular
tachycardia and hyperglycaemia, but that the risk of bradycardia
may be increased. Review authors also concluded that dexmedeto-
midine may not increase the risk of hypotension, atrial fibrillation,
postoperative nausea and vomiting, reintubation within five days,
cardiovascular complications, postoperative infection or hospital
mortality. Additionally, they found no significant differences in
length of intensive care unit (ICU) or hospital stay. An interesting
observation was that the review found no significant differences
in morphine equivalents (mean difference 0.45, 95% CI -1.86
to 2.77; P value = 0.70) between the included studies, which de-
scribed no additional details. Although this observation was made
in a very different setting and in another population than was in-
cluded in our eligibility criteria, it disagrees with findings of our
review and of the above-mentioned reviews.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The findings of our systematic review suggest that dexmedetomi-
dine, compared with placebo, seems to have analgesic and opioid-
sparing effects, but when the comparison is made with placebo,
this is hardly surprising. The analgesic effects seemed to last up
to 24 hours after surgery, even though half of the dexmedetomi-
dine is eliminated from the organism within two hours. Pooled
quantification of the opioid-sparing effect was not possible in this
review, but the opioid-sparing effect was around or above 25% for
most studies during 24 hours after surgery, without a significant
difference in postoperative pain. For our main outcomes, the qual-
ity of the evidence was very low according to the GRADE system,
signifying that “we are very uncertain about the estimate” (Guyatt
2008). We cannot rule out a small-studies effect with overestima-
tion of treatment effects and underreporting of relevant side ef-
fects. Applicability (external validity) of the results was limited to
middle-aged participants with a minimum of co-morbidity when
the reason for abdominal surgery was not considered, and a rela-
tive overweight of bariatric surgery and thus adipose participants
was noted.
Our primary outcomes cannot be separated from one another in
the evaluation of pain and treatment of pain, but what matters to
patients is that they experience a minimum of pain, and in this re-
gard, a presumed opioid-sparing effect of a treatment in itself is not
important to patients. What is more essential involves a reduction
in opioid-related side effects, improved postoperative recovery and
aminimum of other side effects and complications. With selection
of our secondary outcomes (postoperative sedation, postoperative
nausea and vomiting, gastrointestinal function and mobilization),
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we had hoped to be able to evaluate some of these important issues
for patients, but the included studies provided insufficient data.
With practical use of dexmedetomidine, one should still be pre-
pared that side effects, particularly hypotension and bradycardia,
could require intervention. The optimal dosage, timing and route
of administration in the perioperative use of dexmedetomidine
have not been settled.
A comparison of dexmedetomidine with other analgesic agents
has not been possible, as only one of our included studies (20
participants) provided data, with fentanyl as a comparison.
Implications for research
One great limitation of this systematic review was that our choice
to exclude surgery other than abdominal entailed that a great deal
of available data could not be included because they were derived
from studies with mixed surgery (or unspecified), and without
the opportunity to obtain individual participant data. It is not
in our ability to judge whether it can be recommended that fu-
ture research should be more restricted to specific types of surgery,
but it is obvious that future updates of this review would benefit
frommore research restricted to abdominal surgery. Furthermore,
it is likely that studies that investigate mixed surgery, comprising
for example minor or superficial surgery together with abdominal
surgery, may be unlikely to contribute to patient-important out-
comes and side effects that are particularly relevant in abdominal
surgery, such as paralytic ileus, time to mobilization or urinary
retention.
Concerning abdominal surgery, a more exact quantification of the
opioid-sparing effects of dexmedetomidine would of course be
relevant for comparison with other analgesic treatments, but this
should not be a stand-alone aim of future research. Future inves-
tigators must focus on patient-important issues, including out-
comes with a longer period of follow-up. Secondary outcomes of
this review should not be considered as a gold standard check list
for future research, but merely as examples of relevant outcomes
to patients. One could think of many other highly important out-
comes, such as postoperative infection, rehospitalization, delir-
ium, patient satisfaction, chronic postoperative pain and of course
mortality. Larger studies are needed to detect such outcomes.
To pool data in reviews and meta-analyses and compare study
results, it is important to seek consensus concerning evaluation
methods and parameters for outcomes. Areas for possible improve-
ment include evaluation of sedation, the distinction between VAS
pain at rest and at movement, a systematic reporting of baseline
data for evaluated outcomes and a consensus to report postoper-
ative nausea and vomiting as primarily one outcome - PONV -
not separately as nausea and vomiting (because one cannot know
if some participants have both and thereby will count double in
pooling of data, thus causing a unit of analysis error with a meta-
analysis). Furthermore, a report of only VAS pain should never be
provided without a report of amount of ’rescue’ analgesia and vice
versa.
A challenge in performing meta-analyses and reviews of postoper-
ative pain treatment is the great diversity among ’rescue’ analgesia
regimens. Reports of the criteria for administering ’rescue’ analge-
sia provided together with the frequency of evaluation of pain are
relevant data for a systematic review.
Concerning the methodological quality of studies, the description
of random sequence generation, details of blinding methods, allo-
cation concealment methods, etc, should be improved. Without
this detailed information, the judgement ’unclear risk of bias’ may
cover studies that should not have been downgraded and studies
that should have been even further downgraded.
The optimal dosage, timing and route of administration for the
perioperative use of dexmedetomidine in abdominal surgery re-
main to be clarified to show a minimum of harms and a maximum
of benefit. Comparisons of dexmedetomidine with other analgesic
agents are as yet sparse.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bakhamees 2007
Methods RCT
Two parallel groups
Participants Number: 80 (for gender, see notes)
Country: Egypt
Surgery: laparoscopic Roux-en-Y gastric bypass, general anaesthesia, elective
ASA: II or III
Age: 26 to 55 years
Other Inclusion criteria: morbidly obese
Exclusion criteria: clinically significant brain, cardiac, respiratory or liver disease
Interventions • Dexmedetomidine 0.8 µg/kg intravenous bolus over 10 minutes followed by 0.4
µg/kg/h infusion, from beginning until end of surgery (n = 40)
vs
• Normal saline at the same volume and rate (n = 40)
All participants:
◦ Premedication: midazolam 3 mg with glycopyrrolate 0.2 mg.
Metoclopramide 10 mg, ranitidine 50 mg and dexamethazone 8 mg
◦ Anaesthesia and during surgery: fentanyl (0.5 µg/kg), lidocaine (100 mg),
propofol (1 to 2 mg/kg), cisatracurium. Propofol 10 mg/kg/h and titrated until BIS
level between 40 and 60. In both groups, fentanyl (0.5 mg/kg) boluses were given if
blood pressure or heart rate showed 20% increase from baseline
◦ After surgery: nothing reported other than PCA morphine
Outcomes VAS pain 0 to 10 at 2 hours PO
Amount of PCA morphine at 2 hours and 1 day PO
Number of participants with nausea
Number of participants with vomiting
Notes Total amount of intraoperative propofol (mg, mean ± SD) was lower in the dexmedeto-
midine group (1447 ± 310) than in the placebo group (2162 ± 454)
Total amount of intraoperative fentanyl (µg ± SD) was lower in the dexmedetomidine
group (199.4 ± 44.6) than in the placebo group (362.2 ± 57.2)
Study authors contacted for additional information about random sequence generation,
allocation concealment, additional blinding details, gender of participants, etc, without
reply
The article contained an error in report of gender, stating number of men as 34 and
women as 26, leaving the gender of 20 participants unspecified
Risk of bias
Bias Authors’ judgement Support for judgement
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Bakhamees 2007 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “patients...were randomly assigned”
Comment: nothing reported about how randomization was
made
Allocation concealment (selection bias) Unclear risk Nothing reported
Blinding of participants and personnel
(performance bias)
Pain, ’rescue’ analgesia, postoperative seda-
tion
Low risk Quote: “Patients and investigators recording data in the
operating room were blinded to the treatment..., but the
anaesthesiologist was aware of the treatment condition. The
same surgeon performed all of the surgeries”
Comment: No blinding of the anaesthesiologist may
have influenced the administered amount of intraoperative
propofol and fentanyl, which was higher in the placebo
group for both drugs. Particularly fentanyl could have an in-
fluence on the postoperative need for PCA morphine. Tak-
ing the direction of this bias into account, the actual mea-
sured effect was an underestimate, and therefore the risk of
bias was low. Participants were blinded, and this was essen-
tial for a low risk of bias concerning PCA morphine
Blinding of participants and personnel
(performance bias)
PONV
Unclear risk Quote: same as above
Comment: same as comment above - not only fentanyl but
also propofol could have an influence on PONV. In this
case, however, the direction of bias was not clear
Blinding of participants and personnel
(performance bias)
Time to first passage of flatus or stool
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Time to first out-of-bed mobilization
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Post-interventional complications or side
effects
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Pain, ’rescue’ analgesia, postoperative seda-
tion
Low risk Quote: “investigators recording data in the operating room
were blinded to the treatment”
Quote: “pain scores were obtained...by a nurse who was
blinded to the treatment procedure”
Comment: probably done. Amount of PCA morphine was
probably assessed by the same nurse who was assessing pain
scores
Blinding of outcome assessment (detection
bias)
PONV
Unclear risk Quote: “investigators recording data in the operating room
were blinded to the treatment”
Quote: “pain scores were obtained...by a nurse who was
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Bakhamees 2007 (Continued)
blinded to the treatment procedure”
Comment: not explicitly stated for PONV
Blinding of outcome assessment (detection
bias)
Time to first passage of flatus or stool
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Time to first out-of-bed mobilization
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Post-interventional complications or side
effects
Unclear risk Not relevant
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data
Selective reporting (reporting bias) Low risk Comment: No protocol available, but all outcomes men-
tioned in Methods section reported quantitatively and for
all prespecified time points
Other bias Low risk No other apparent bias
Feld 2006
Methods RCT, 2 parallel groups
Participants Number: 20 men (n = 7) and women (n = 13)
Country: USA
Surgery: open gastric bypass, general anaesthesia, elective
ASA: II or III
Age: 26 to 55 years
Other inclusion criteria: bariatric patients
Exclusion criteria: pregnancy, clinically significant brain, cardiac, respiratory or liver
disease
Interventions • Dexmedetomidine 0.5 µg/kg intravenous bolus followed by infusion 0.4 µg/kg/h
(n = 10)
vs
• Fentanyl 0.5 µg/kg intravenous bolus followed by infusion 0.5 µg/kg/h (n = 10)
All participants:
◦ Premedication: midazolam 2 mg
◦ Anaesthesia and during surgery: lidocaine (100 mg), thiopental (1 to 4 mg/kg)
and succinylcholine (0.6 mg/kg). Desflurane adjusted to maintain BIS at 45 to 50
◦ After surgery: nothing reported other than PCA morphine
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Feld 2006 (Continued)
Outcomes VAS pain at 2 hours PO, reported as median and range
Amount of PCA morphine at 2 hours PO
Post-interventional complications reported post hoc: number of participants with hy-
potension requiring intervention and number of participants requiring prolonged me-
chanical ventilation
Notes Less thiopental (mg/kg, mean ± SD) was used for induction of anaesthesia in the
dexmedetomidine group (2.1 ± 0.5) compared with the fentanyl group (3.1 ± 0.6)
The dexmedetomidine group required less desflurane concentration compared with the
fentanyl group to maintain the target BIS level
Time of follow-up was 2 hours PO
Baseline characteristics concerningheight, weight andbodymass index probably reported
with error. Study authorswere contacted for this additional information, including details
of allocation concealment, without luck
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomized using a computer-gener-
ated random number table”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Nothing reported
Blinding of participants and personnel
(performance bias)
Pain, ’rescue’ analgesia, postoperative seda-
tion
Low risk Quote: “Patients and investigators recording data in the op-
erating room were blinded to the treatment..., but the anaes-
thesiologist was aware of the treatment condition. The same
surgeon performed all of the surgeries”
Comment: incomplete blinding, but unlikely to have an effect
on the need for rescue analgesia
Blinding of participants and personnel
(performance bias)
PONV
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Time to first passage of flatus or stool
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Time to first out-of-bed mobilization
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Post-interventional complications or side
effects
High risk Quote: “Patients and investigators recording data in the op-
erating room were blinded to the treatment..., but the anaes-
thesiologist was aware of the treatment condition. The same
surgeon performed all of the surgeries”
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Feld 2006 (Continued)
Comment: No blinding of the anaesthesiologist may have in-
fluenced the administered amount of intraoperative desflurane,
which was higher in the fentanyl group. This may have influ-
enced post-interventional complications, in particular circula-
tory complications for which no report provided prespecified
criteria for giving epinephrine
Blinding of outcome assessment (detection
bias)
Pain, ’rescue’ analgesia, postoperative seda-
tion
Low risk Quote: “investigators recording data in the operating room
were blinded to the treatment”
Quote: “VAS pain, heart rate and blood pressure were recorded
postoperatively by a nurse blinded to the treatment procedure”
Comment: Amount of PCA morphine probably was assessed
by the same nurse who was assessing pain scores
Blinding of outcome assessment (detection
bias)
PONV
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Time to first passage of flatus or stool
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Time to first out-of-bed mobilization
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Post-interventional complications or side
effects
High risk Quote: “Patients and investigators recording data in the op-
erating room were blinded to the treatment..., but the anaes-
thesiologist was aware of the treatment condition. The same
surgeon performed all of the surgeries”
Quote: “VAS pain, heart rate and blood pressure were recorded
postoperatively by a nurse blinded to the treatment procedure”
Comment: The non-blinded anaesthesiologist was likely to
have had a role in assessment and treatment of circulatory and
respiratory complications
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data
Selective reporting (reporting bias) High risk No protocol available. Regarding the post-interventional com-
plications reported post hoc, prolonged mechanical ventila-
tion could not have been foreseen, but hypotension requir-
ing intervention (epinephrine 25 mg intramuscularly) could
have been prespecified, and the criteria for giving epinephrine
should have been prespecified
Other bias Low risk No other apparent bias
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Khanduja 2013
Methods RCT, single-blinded, 2 parallel groups
Participants Number: 60 men (n = 12) and women (n = 48)
Country: India
Surgery: laparoscopic cholecystectomy, general anaesthesia, elective
ASA: not reported, probably I and II (judged by exclusion criteria)
Age: 20 to 65 years
Other inclusion criteria: none reported
Exclusion criteria: anaemia, long-term medications or any medication within 1 week
before surgery, history of any chronic disease, cardiac problem, history of drug abuse,
consumption of more than 30 g alcohol/d, use of β-blockers and abnormal preoperative
electrolyte concentrations
Interventions • Dexmedetomidine 0.5 µg/kg/h intravenous infusion initiated 30 minutes before
induction and augmented to 0.6 µg/kg/h after induction of anaesthesia
vs
• Normal saline at the same volume
All participants:
◦ Premedication: esomeprazole 40 mg the night before surgery
◦ Anaesthesia and during surgery: 2 minutes before induction, pentazocine 0.5
mg/kg in control group and 0.3 mg/kg in dexmedetomidine group. Glycopyrrolate 0.2
mg, thiopentone sodium 2 mg/kg plus repeated boluses of 25 mg, succinylcholine
hydrochloride (1.5 mg/kg). End-inspiratory isoflurane 1.2% in the control group and
0.6% in the dexmedetomidine group. Rocuronium 0.8 mg/kg, neostigmine 2.5 mg,
glycopyrrolate 0.4 mg. Additional boluses of pentazocine (0.1 mg/kg) were
administered on signs of intraoperative pain
◦ After surgery: Patients were given an extra dose of pentazocine on complaint
of immediate postoperative pain. Nothing else reported
Outcomes Number of participants with postoperative pain. No time point specified, but probably
immediately after extubation
Notes A significant difference was reported in the total amount of administered pentazocine
(mg, mean, SD): 17.9 ± 4.13 in the dexmedetomidine group vs 29.4 ± 4.272 in the
placebo group (P value < 0.001), including intraoperative need and predetermined dif-
ference in induction dose
Duration of study ≥ 30 minutes after surgery, not further specified
Study authors contacted for details of follow-up, random sequence generation, allocation
concealment, etc, without luck
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “...randomized...”
Comment: not reported how
Allocation concealment (selection bias) Unclear risk Nothing reported
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Khanduja 2013 (Continued)
Blinding of participants and personnel
(performance bias)
Pain, ’rescue’ analgesia, postoperative seda-
tion
Low risk Quote: “ ...single blinded...”
Comment: probably non-blinded anaesthesi-
ologist assessing all outcomes (time of follow-
up approximately 30 minutes after surgery).
This could have influenced the intraoperatively
administered amount of pentazocine, which
was significantly different between groups. An
unblinded anaesthesiologist might have an in-
terest in showing reduced need for intraoper-
ative analgesia/anaesthesia in the intervention
group, or he might anticipate that participants
would have more pain. Thus, the possible di-
rection of bias would be to underestimate the
effect of intervention; therefore the risk of bias
was low
Blinding of participants and personnel
(performance bias)
PONV
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Time to first passage of flatus or stool
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Time to first out-of-bed mobilization
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Post-interventional complications or side
effects
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Pain, ’rescue’ analgesia, postoperative seda-
tion
Low risk Quote: “...single blinded...”
Comment: the same comment as under per-
formance bias
Blinding of outcome assessment (detection
bias)
PONV
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Time to first passage of flatus or stool
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Time to first out-of-bed mobilization
Unclear risk Not relevant
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Khanduja 2013 (Continued)
Blinding of outcome assessment (detection
bias)
Post-interventional complications or side
effects
Unclear risk Not relevant
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data
Selective reporting (reporting bias) Unclear risk Insufficient information to allow a judgement;
no protocol available
Other bias Unclear risk Insufficient information to allow a clear judge-
ment
Mohamed 2012
Methods RCT, 3 parallel groups
Participants Number: 90 men (n = 30) and women (n = 60)
Country: Egypt
Surgery: major abdominal cancer surgery, general anaesthesia, elective
Age: 25 to 55 years
ASA: I or II
Other inclusion criteria: weight 50 to 85 kg
Exclusion criteria: allergy, bleeding diathesis, liver/renal dysfunction, drug/alcohol
abuse, psychiatric illness interfering with pain assessment
Interventions • Dexmedetomidine group: 10 mg bupivacaine 0.5% plus 5 µg dexmedetomidine
(n = 30)
vs
• Dexmedetomidine plus fentanyl group: 10 mg bupivacaine 0.5% plus 5 µg
dexmedetomidine and 25 µg fentanyl (n = 30)
◦ Interventions made as bolus only, everything intrathecally administered
before induction of general anaesthesia, and no infusion
vs
• Control group: 10 mg bupivacaine 0.5% (n = 30)
All participants:
◦ Premedication: oral diazepam 5 mg the night before surgery
◦ Anaesthesia and during surgery: anaesthetic agents not described. In case of
hypotension (15% decrease from baseline): ephedrine 0.1 mg/kg and saline 5 mL/kg.
In case of bradycardia (< 50 beats/min): atropine 0.01 mg/kg iv. Ringer’s solution 10
mL/kg before spinal anaesthesia
◦ After surgery: nothing reported other than rescue analgesia (tramadol)
Outcomes Total analgesic consumption during 24 hours (intravenous tramadol 100 mg when VAS
≥ 3 or on participant’s request)
VAS pain at PACU arrival and at 2, 4, 6, 8, 12 and 24 hours PO
Time to first request of analgesia
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Number of participants with nausea during 24 hours PO
Number of participants with vomiting during 24 hours PO
Notes Nausea and vomiting are reported as 2 separate outcomes
Postoperative sedation score was measured with 5-scale Observer’s Assessment of Alert-
ness/Sedation (OAA/S) scale, but with no specified time points and nothing else reported
than “no significance between groups”
Please note that ASA was judged to be I, even if participants were known to have
abdominal cancer
No information about specific type of surgery (which type of cancer, laparoscopic vs
open)
Study authors contacted about the above mentioned and details of relevance for risk of
bias assessment, without reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “this randomized trial...”
Quote: “patients were allocated to one of 3 groups...”
Comment: unclear whether it was done correctly
Allocation concealment (selection bias) Unclear risk Comment: nothing reported, only description of syringes that
were of same volume (2 mL plus 1 mL) for each intervention
group.Unclearwhether the allocation could have been foreseen
Blinding of participants and personnel
(performance bias)
Pain, ’rescue’ analgesia, postoperative seda-
tion
Unclear risk Quote: “this double-blind trial...”
Comment: insufficient information to allow a clear judgement
Blinding of participants and personnel
(performance bias)
PONV
Unclear risk Quote: “this double-blind trial...”
Comment: insufficient information to allow a clear judgement
Blinding of participants and personnel
(performance bias)
Time to first passage of flatus or stool
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Time to first out-of-bed mobilization
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Post-interventional complications or side
effects
Unclear risk Quote: “this double-blind trial...”
Comment: insufficient information to allow a clear judgement
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Blinding of outcome assessment (detection
bias)
Pain, ’rescue’ analgesia, postoperative seda-
tion
Unclear risk Quote: “this double-blind trial...”
Comment: insufficient information to allow a clear judgement
Blinding of outcome assessment (detection
bias)
PONV
Unclear risk Quote: “this double-blind trial...”
Comment: insufficient information to allow a clear judgement
Blinding of outcome assessment (detection
bias)
Time to first passage of flatus or stool
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Time to first out-of-bed mobilization
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Post-interventional complications or side
effects
Unclear risk Quote: “this double-blind trial...”
Comment: insufficient information to allow a clear judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data
Selective reporting (reporting bias) High risk No protocol available, and data concerning postoperative se-
dation are reported only as “no significance between groups”
and no time points specified
Other bias High risk Nothing was reported about differences in anaesthetic agents
between groups
No reports on which type of surgery, other than major abdom-
inal cancer surgery. Participants received an amount of ’res-
cue’ analgesia during 24 hours postoperatively with a remark-
ably small standard deviation (see Analysis 1.2), which makes
a more detailed report of anaesthetic agents and any difference
between groups required
Park 2012
Methods RCT, 2 parallel groups
Participants Number: 42 men (n = 19) and women (n = 23)
Country: Korea
Surgery: laparoscopic cholecystectomy, general anaesthesia, elective
Age: 18 to 60 years
ASA: I or II
Other inclusion criteria: none reported
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Exclusion criteria: body mass index > 30 kg/m2, allergy to any medications, renal or
hepatic insufficiency, neurological or psychiatric disease, preoperative heart rate < 45
beats/min, antihypertensive medication with clonidine or other alpha-2 agonist
Interventions • Dexmedetomidine 1 µg/kg as intravenous bolus over 10 minutes before induction
of anaesthesia and then 0.5 µg/kg/h continuously until removal of the gall bladder (n =
21)
vs
• Normal saline administered in the same way (n = 21)
All participants:
◦ Premedication: glycopyrrolate 0.2 mg
◦ Anaesthesia and during surgery: propofol (1.0 mg/kg initially and repeated
bolus of 10 mg until BIS score < 60). Rocuronium 0.6 mg/kg. Sevoflurane.
Neostigmine and glycopyrrolate. If heart rate was < 40 beats/min, atropine 0.5 mg was
administered to participants. Ephedrine 10 to 20 mg if systolic blood pressure < 80
mmHg. Ketorolac 30 mg and dexamethasone 8 mg after induction of anaesthesia.
Beforecreation of pneumoperitoneum, 0.25% bupivacaine (3 mL) was infiltrated
intracutaneously and subcutaneously at each trocar insertion site
◦ After surgery: ondansetron 4 mg in case of PONV, repeated if necessary
Outcomes VAS pain at 6 and 24 hours PO
Total amount of intravenous ’rescue’ tramadol at 24 hours PO (when the patient re-
quested analgesics or had VAS pain > 4, 30 mg of ketorolac was injected intravenously;
30 minutes later if VAS was still higher than 4, patients received tramadol 50 mg intra-
venous boluses. If VAS pain was still greater than 4 after another 30 minutes, 20 µg of
intravenous fentanyl was administered)
Notes The amount of propofol differed between groups with (mg, mean, SD) 83 ± 23.4 in the
dexmedetomidine group vs 117 ± 33.9 in the placebo group
No report described the amount of rescue fentanyl. It was reported that 2 participants in
the control group and none in the intervention group needed administration of fentanyl.
No report on the number of participants needing ketorolac and tramadol; only total
amounts administered were reported, showing a significant difference between groups
for intravenous ketorolac (mg, mean, SD) with 43.5 ± 18 in the dexmedetomidine group
vs 66 ± 39.6 in the placebo group
Study authors contacted for details of relevance for risk of bias assessment, without luck
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly allocated”
Comment: Nothing else stated. Unclear how it was done
Allocation concealment (selection bias) Unclear risk Nothing reported
Blinding of participants and personnel
(performance bias)
Pain, ’rescue’ analgesia, postoperative seda-
Unclear risk Nothing reported
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tion
Blinding of participants and personnel
(performance bias)
PONV
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Time to first passage of flatus or stool
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Time to first out-of-bed mobilization
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Post-interventional complications or side
effects
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Pain, ’rescue’ analgesia, postoperative seda-
tion
Unclear risk Quote: VAS pain was assessed “after operation by an anaesthe-
siologist who was not involved in the study”
Comment: Nothing stated about rescue analgesia, but one
might assume that the analgesia was administered by the same
person assessing VAS pain. But as nothing was reported about
blinding of participants, risk of bias remained unclear
Blinding of outcome assessment (detection
bias)
PONV
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Time to first passage of flatus or stool
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Time to first out-of-bed mobilization
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Post-interventional complications or side
effects
Unclear risk Not relevant
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data
Selective reporting (reporting bias) High risk Noprotocol was available. Several outcomeswere not prespeci-
fied but seemed tobe determinedpost hoc, anduse of antiemet-
ics among patients with PONV was measured according to
the Methods section but was not reported. Amount of rescue
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analgesia was not prespecified but probably was intended as
an outcome pre hoc. Time points preselected for VAS pain
were not exactly the same as those reported (prespecified time
points 8 and 12 hours postoperatively were reported at 6 and
8 hours instead)
Other bias Unclear risk Insufficient information to allow a clear judgement
Tufanogullari 2008
Methods RCT, 4 parallel groups
Participants Number: 80 men (n = 19) and women (n = 61)
Country: USA
Surgery: laparoscopic bariatric surgery (gastric banding or gastric bypass), general anaes-
thesia, elective
Age: 22 to 66 years
ASA: II or III
Other inclusion criteria: none reported
Exclusion criteria: allergy to alpha-2 adrenergic agonists or sulpha drugs; uncontrolled
hypertension; heart block greater than first degree; alcohol or drug abuse; neurological,
cardiovascular, renal, hepatic or gastrointestinal disease; opioid analgesic medication
within 24 hours; pregnancy or breast-feeding; inability to speak and read English
Interventions • DEX 0.2 group: dexmedetomidine 0.2 µg/kg/h (n = 20)
vs
• DEX 0.4 group: dexmedetomidine 0.4 µg/kg/h (n = 20)
vs
• DEX 0.8 group: dexmedetomidine 0.8 µg/kg/h (n = 20)
vs
• Control group: saline infusion (n = 20)
◦ For all groups, an intravenous infusion started before induction for
anaesthesia and throughout surgery, and no bolus
All participants:
◦ Premedication: midazolam 20 µg/kg, celecoxib 400 mg orally
◦ Anaesthesia and during surgery: propofol 1.25 mg/kg, lidocaine 0.75 mg/kg.
Rocuronium 0.6 mg/kg. Desflurane. Crystalloid solution 25 mL/kg for gastric bypass
and 10 mL/kg for gastric banding. Neostigmine 40 µg/kg and glycopyrrolate 5 µg/kg
◦ After surgery: ondansetron 4 mg when the laparoscope was withdrawn. Before
wound closure, bupivacaine 0.25% was infiltrated at the fascial level of all portals
Outcomes Amount of ’rescue’ analgesia:
• Fentanyl, 25 to 50 µg boluses during initial time in PACU, given by personnel
until PCA morphine was possible
• PCA morphine on postoperative day 1 (initiated when verbal response scale
(VRS) pain score was < 7 and after recovery from anaesthesia)
• Hydromorphone (2,5 mg/mL)-acetaminophen (167 mg/mL) orally on
postoperative day 1
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VRS pain 0 to 10 after 1 day PO
Number of participants needing ’rescue’ opioid after 1 day PO
Number of participants with nausea during stay in PACU
Number of participants with vomiting during stay in PACU
Number of participants requiring antiemetics during stay in PACU (intravenous promet-
hazine 6.25 mg administered if VRS nausea score > 3 on 2 consecutive evaluations)
VRS nausea scores 0 to 10 at 30-minute intervals until PACU discharge
Time to passing flatus (participants making a diary note)
Time to ambulation without assistance
Number of participants with post-interventional complications or side effects:
• Hypertension and/or tachycardia requiring ’rescue’ beta-blocker (after increased
anaesthesia)
• Hypotension requiring rescue phenylephrine (after reduction in anaesthesia and
200 mL fluid)
Notes Study authors contacted for supplementary information about ’rescue’ analgesia regimen
and details about PONV, without reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...a computer-generated random number table”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote: “The study medication was prepared by the operating
room (OR) pharmacist in identical 60-mL syringes. DEX 0,
200, 400, or 800 µg was added to saline to achieve a total
volume of 40 mL... for the 4 study groups...An infusion of the
study medication was started at 0.04 mL/kg/h”
Quote: “The investigators, attending anaesthesiologists, OR,
recovery and ward nurses, as well as the patients were blinded
to the computer-generated randomization schedule”
Comment: probably done
Blinding of participants and personnel
(performance bias)
Pain, ’rescue’ analgesia, postoperative seda-
tion
Low risk Quote: “The investigators, attending anaesthesiologists, OR,
recovery and ward nurses, as well as the patients were blinded
to the computer-generated randomization schedule”
Comment: probably done
Blinding of participants and personnel
(performance bias)
PONV
Low risk Same as above
Blinding of participants and personnel
(performance bias)
Time to first passage of flatus or stool
Low risk Same as above
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Blinding of participants and personnel
(performance bias)
Time to first out-of-bed mobilization
Low risk Same as above
Blinding of participants and personnel
(performance bias)
Post-interventional complications or side
effects
Low risk Same as above
Blinding of outcome assessment (detection
bias)
Pain, ’rescue’ analgesia, postoperative seda-
tion
Low risk Same as above
Blinding of outcome assessment (detection
bias)
PONV
Low risk Same as above
Blinding of outcome assessment (detection
bias)
Time to first passage of flatus or stool
Low risk Same as above
Blinding of outcome assessment (detection
bias)
Time to first out-of-bed mobilization
Low risk Same as above
Blinding of outcome assessment (detection
bias)
Post-interventional complications or side
effects
Low risk Same as above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Three patients (one from each of the DEX 0.2, 0.4,
and 0.8 groups) were admitted to the intensive care unit from
the postsurgical ward because of surgical complications at the
gastrointestinal anastomosis site (e.g., bleeding, obstruction)
and their postoperative data were excluded from the final anal-
ysis”
Comment: As participants were excluded for surgical reasons
and were equally distributed, risk of bias was probably low
Selective reporting (reporting bias) Unclear risk The published article was in line with the protocol, which was
available, but outcomes were described in very general terms
only. Two outcomes seemed to be added post hoc (number of
participants discharged on postoperative day 1 and number of
days until discharge), but they showed no significant differ-
ences between groups
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Other bias High risk Comment: Criteria for the use of analgesia were not clearly
described, even though participants went through a complex
3-step rescue analgesia regimen. As VRS pain scores were col-
lected only in the PACU and on postoperative days 1 and 2,
one might suspect some irregularities in the way analgesia was
administered. Information given to participants on how to ad-
minister the analgesia at home was not described. One might
suspect lack of control of participant compliance at home,
leading to high risk of bias
Quote: “This investigator-initiated, Food and Drug Admin-
istration-approved study was supported, in part, by an unre-
stricted educational grant from Hospira, Inc.a (Lake Forest,
IL), endowment funds from the Margaret Milam McDermott
Distinguished Chair in Anesthesiology, and the White Moun-
tain Institute, a non-profit private foundation (Paul F. White,
President)”
Quote (from authors’ conclusion): “Our findings would sug-
gest that the modest anaesthetic-sparing effect was of little (if
any) clinical significance because dexmedetomidine failed to
facilitate a faster emergence from desflurane anaesthesia after
bariatric surgery. (…) the primary benefit of Dex in this study
appeared to be related to its ability to reduce emetic sequelae
by decreasing the need for the desflurane during the operation
and fentanyl immediately after surgery”
Comment: The potential conflict of interest is of unclear im-
portance. The conclusion of the study authors seem modest
and reasonable, but it is not stated in what way the grant was
’unrestricted’ (e.g. if Hospira owned the data or needed to ap-
prove of the manuscript)
Xiao 2013
Methods RCT, 3 parallel groups
Participants Number: 120 men (n = 53) and women (n = 67)
Country: China
Surgery: open abdominal surgery, general anaesthesia, elective
Age: 18 to 60 years
ASA: I or II
Other inclusion criteria: expected duration of surgery > 45 minutes
Exclusion criteria: body mass index > 28 kg/m2; metabolic diseases such as diabetes,
hyperthyroidism; serious cardiovascular disease; alcohol or illicit drugs; mental illness or
epilepsy
Interventions • Dexmedetomidine 1 µg/kg intravenous bolus after induction of anaesthesia plus
remifentanil infusion 0.4 µg/kg/min intraoperatively (n = 40)
vs
• Bolus of normal saline at same volume plus remifentanil infusion 0.4 µg/kg/min
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intraoperatively (n = 40)
vs
• Bolus of normal saline plus remifentanil infusion 0.05 µg/kg/min intraoperatively
(n = 40)
All participants:
◦ Premedication: none reported
◦ Anaesthesia and during surgery: propofol 2 mg/kg, remifentanil 2 µg/kg,
rocuronium 0.6 mg/kg. Sevoflurane, rocuronium injected every 40 minutes
◦ After surgery: intravenous morphine when needed, not further specified
Outcomes Dose of ’rescue’ morphine at 12 and 24 hours PO
Postoperative pain measured by VAS at 12 and 24 hours
Postoperative sedation measured by RSS at 12 and 24 hours
Notes This review looked at only 2 of the 3 parallel groups in this study
Amounts of intraoperative sevoflurane, remifentanil and phenylephrine did not differ
significantly between the 2 groups analysed by this review. Investigators reported signif-
icant differences for these 3 drugs when compared with low-dose remifentanil
Study available only in Chinese. Qualitative data extracted by only 1 person, the trans-
lator, whereas quantitative data were extracted by the review authors from tables with
no need of translation. Study authors contacted in English for additional information
of relevance for risk of bias assessment, type of surgery, criteria for ’rescue’ analgesia, etc,
without luck
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”...random number table was used to generate random
sequence...“
Comment: probably done
Allocation concealment (selection bias) Unclear risk Nothing reported
Blinding of participants and personnel
(performance bias)
Pain, ’rescue’ analgesia, postoperative seda-
tion
Unclear risk Quote: ”this is a double-blind randomized controlled trial”
Comment: nothing else reported, unclear how blinding was
done
Blinding of participants and personnel
(performance bias)
PONV
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Time to first passage of flatus or stool
Unclear risk Not relevant
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Blinding of participants and personnel
(performance bias)
Time to first out-of-bed mobilization
Unclear risk Not relevant
Blinding of participants and personnel
(performance bias)
Post-interventional complications or side
effects
Unclear risk Quote: “this is a double-blind randomized controlled trial”
Comment: nothing else reported, unclear how blinding was
done
Blinding of outcome assessment (detection
bias)
Pain, ’rescue’ analgesia, postoperative seda-
tion
Unclear risk Same as above
Blinding of outcome assessment (detection
bias)
PONV
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Time to first passage of flatus or stool
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Time to first out-of-bed mobilization
Unclear risk Not relevant
Blinding of outcome assessment (detection
bias)
Post-interventional complications or side
effects
Unclear risk Quote: ”this is a double-blind randomized controlled trial”
Comment: nothing else reported, unclear how blinding was
done
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk All outcomes described in theMethods section were accounted
for in the Results section
Other bias Unclear risk Incomplete information to allow a clear judgement
RCT: randomized controlled trial; ASA: American Society of Anesthesiologists Physical Status 1 to 6, where 1 = Healthy person, 2 =
Mild systemic disease, 3 = Severe systemic disease, 4 = Severe systemic disease that is a constant threat to life, 5 = A moribund person
who is not expected to survive without the operation, 6 = A declared brain-dead person whose organs are being removed for donor
purposes; BIS: bispectral index, a measure of electroencephalography (EEG)-based depth of anaesthesia; PCA: patient-controlled
analgesia; VAS: visual analogue scale; PO: postoperative; SD: standard deviation; PONV: postoperative nausea and vomiting; PACU:
post-anaesthesia care unit; DEX: dexmedetomidine; RSS: Ramsey Sedation Scale 1 to 6, where 1 = Patient is anxious and agitated
or restless or both; 2 = Patient is co-operative, oriented and tranquil, 3 = Patient responds to commands only, 4 = Patient exhibits
brisk response to light glabellar tap or loud auditory stimulus, 5 = Patient exhibits a sluggish response to light glabellar tap or loud
auditory stimulus, 6 = Patient exhibits no response. aHospira is a manufacturer of dexmedetomidine
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdalla 2003 Cystectomy
Akinci 2011 Three intervention groups with different doses of dexmedetomidine, but no control group
Aldehayat 2011 No relevant outcomes
Arain 2002 Hernia repair and orthopaedic surgery
Basar 2008 No relevant outcomes
Bergese 2010 No relevant outcomes
Bhattacharjee 2010 No relevant outcomes
Candiotti 2010 Not abdominal surgery
Chen 2013 No relevant outcomes
Elcicek 2010 Lower extremity surgery
Gupta 2011 Gynaecological and urological surgery and hernia repair
Gupta 2014a Abdominal hysterectomy and inguinal hernioplasty
Gupta 2014b Plastic and otorhinolaryngological surgery, but also regional ’general surgery’ of duration about 1 hour. Study
authors emailed to confirm which type, but no reply. Excluded as it probably was not abdominal surgery
Gurbet 2006 Intra-abdominal hysterectomy
Guryanov 2013 Intensive care unit (in Russian only, data extracted on a voluntary basis by a native Russian medical search
expert within The Cochrane Collaboration)
Harsoor 2014 Relevant outcomes are not reported at time points collected by this review. Ramsay Sedation Scale and visual
analogue scale (VAS) pain are reported only after 1 hour postoperatively
Iwakiri 2012 Gynaecological surgery
Jakob 2012 Dexmedetomidine given for sedation in intensive care unit
Kaya 2010 Urological surgery
Keniya 2011 Not abdominal surgery
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Lawrence 1997 Only orthopaedic and superficial surgery (hernia repair, pilonidal sinus, varicose veins, hydrocoele)
Marangoni 2005 Dexmedetomidine not the sole difference between intervention and control groups. The study compared
sufentanil vs dexmedetomidine plus midazolam
Málek 2010 Intervention groups with too many agents and interactions:
• Dexmedetomidine and ketamine and fentanyl and atropine
vs
• Dexmedetomidine and ketamine
vs
• Alfentanil and atropine
vs
• Petidine and atropine
No author 2007 Abdominal hysterectomy
Ohtani 2008 Gynaecological surgery
Ozbakis 2008 Gynaecological and urological surgery (full text not retrievable, but information about specific type of surgery
was found in Schnabel 2013)
Padma 2013 Dexmedetomidine not administered perioperatively
Shukla 2011 No relevant outcomes
Tasdogan 2009 Dexmedetomidine administered in intensive care unit and not perioperatively
Wan 2011 Dexmedetomidine administered in intensive care unit and not perioperatively
Yildiz 2006 Other minor surgery
Zeng 2014 Nephrectomy
Characteristics of studies awaiting assessment [ordered by study ID]
Altindis 2008
Methods RCT, 2 parallel groups
Participants Number: 40 participants
Country: Turkey
Surgery: lower abdominal surgery
Age: 21 to 56 years
ASA: I or II
Other inclusion criteria: general anaesthesia
Exclusion criteria: history of hypertension, ischaemic heart disease or conduction disturbance; history of alcohol or
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drug abuse; use of beta-adrenoreceptor blockers, monoamine oxidase inhibitor within 2 weeks; impaired hepatic or
renal function; hypersensitivity to opioids or dexmedetomidine
Interventions • Meperidine 0.25 mg/kg intravenous bolus and dexmedetomidine 0.5 µg/kg in 50 mL of saline solution
infused during the 10 minutes before the end of surgery
vs
• Meperidine 0.25 mg/kg intravenous bolus and 50 mL of saline solution infusion during 10 minutes before the
end of surgery
All participants:
◦ Premedication: 10 mg 2 hours before surgery
◦ After surgery: PCA during 24 hours after surgery. PCA settings were as follows: meperidine 5 mg plus
dexmedetomidine 10 µg bolus dose for Group I, and meperidine 5 mg bolus dose for Group II
Outcomes Verbal rating score for pain (0 to 3)
Total meperidine consumption
Time to discharge from PACU
Postoperative sedation (0 to 3)
Number of participants with postoperative vomiting
Hemodynamic data
Notes Study authors contacted to clarify types of surgery. No reply
Anvaroglu 2008
Methods RCT, 2 parallel groups
Participants Number: 50 participants, all female
Country: Turkey
Surgery: abdominal surgery
Age: 20 to 60 years
ASA: I to II
Other inclusion criteria: general anaesthesia
Exclusion criteria: none stated
Interventions • Dexmedetomidine 0.5 µg/kg intravenous bolus over 10 minutes before induction of anaesthesia and 0.5 µg/
kg/h until end of surgery
vs
• Saline 0,9 % administered in the same way
Outcomes Total analgesic consumption
Notes Type of surgery unknown. We were unable to locate anything but an abstract. Study authors would have been
contacted if we could have located an address
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Methods RCT, 2 parallel groups
Participants Number: 34 participants (gender not reported)
Country: USA
Type of surgery: intra-abdominal (15), major orthopaedic (13), other (6)
Age: adults, mean age 60 years
ASA: I to III
Other inclusion criteria: normal renal function, scheduled for at least a 24-hour stay in the hospital
Exclusion criteria: second- or third-degree heart block, use of any experimental drug, including dexmedetomidine
or other alpha-2 agonists within 28 days, long-term use of medical therapy that might influence the outcome of the
study (such as opioids), current history of psychiatric disorder or presently taking psychotropic medications, ejection
fraction < 30%, sleep apnoea, BMI > 35 kg/m2
Interventions • Dexmedetomidine 1 µg/kg intravenous bolus over 10 minutes followed by 0.4 µg/kg/h at 30 minutes before
end of surgery and until end of surgery (n = 17)
vs
• Morphine 0.08 mg/kg intravenous bolus at 30 minutes before end of surgery (n = 17)
All participants:
◦ Premedication: fentanyl (0.7 µg/kg) and midazolam (0.02 to 0.04 mg/kg)
◦ Anaesthesia and during surgery: sevoflurane and fentanyl with no difference between groups
◦ After surgery: additional morphine 2 mg intravenously administered by nurse in PACU if visual analogue
scale (VAS) pain > 50 mm, evaluated every 5 minutes, changing to PCA morphine on the ward during 24 hours
(length of stay in PACU not reported)
Outcomes VAS postoperative sedation (0 to 100 mm, where 100 = wide awake) regularly during 100 minutes after surgery
VAS postoperative pain regularly during first 100 minutes after surgery
VAS 0 to 100 postoperative nausea during first 100 minutes after surgery
Number of participants with need for additional morphine at 30 and 60 minutes after surgery
Amount of ’rescue’ morphine during 30 minutes after surgery
Amount (increments) of PCA morphine during 24 hours on the ward (no total, but frequent time points)
Notes PCA morphine data were lost from 4 participants (2 from each group)
Study authors contacted for individual participant data, as this review does not look at orthopaedic surgery. No reply
Bicer 2006
Methods RCT, 3 parallel groups
Participants Number: 120 men (n = 74) and women (n = 46)
Country: Turkey
Surgery: elective abdominal and orthopaedic, lasting 1 to 3 hours
Age: 18 to 50 years
ASA: I to II
Other inclusion criteria: none stated
Exclusion criteria: BMI > 27 kg/m2; fever; use of vasoactive, antidepressant or analgesic drugs; history of cardiovas-
cular, respiratory, endocrine or neurological disease; pregnancy
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Interventions • Dexmedetomidine 1 µg/kg intravenously at the time of wound closure (n = 40)
vs
• Meperidine 0.5 µg/kg intravenously at the time of wound closure (n = 40)
vs
• Saline 0,9% at the time of wound closure (n = 40)
Outcomes Postoperative sedation, grade 1 to 6
Postoperative pain, grade 0 to 4
Postoperative nausea and vomiting
Postoperative analgesic requirements (not specifying type of analgesia)
Postoperative antiemetic requirements
Notes Study authors contacted for type of abdominal surgery and individual participant data, and to obtain data on type of
rescue analgesia and data on postanaesthetic pain. Study authors sent 1 reply, but not to the above mentioned details.
Awaiting new reply
Ceballos 2011
Methods RCT, 2 parallel groups
Participants Number: 91 men (n = 46) and women (n = 45)
Country: Mexico
Surgery: bariatric, no description of open/laparoscopic (probably laparoscopic because they stated that modern
technique was used)
Age: 18 to 65 years
ASA: not reported (probably primarily ASA II)
Other inclusion criteria: BMI > 32 kg/m2, less than 10 years of diabetes, less than 5 years of treatment with insulin,
proper control of co-morbidity
Exclusion criteria: none reported
Interventions • Dexmedetomidine bolus of 1.0 µg/kg of ideal body weight (Ideal weight (kg) = Height (cm) - 100),
administered with 250 mL of saline 0.9% over 10 minutes before surgery (n = 45)
vs
• Control group, not mentioned if saline is used as placebo (n = 46)
All participants:
◦ Premedication: none
◦ Anaesthesia and during surgery: Induction with fentanyl 5 µg/kg of actual weight, propofol 2 mg/kg of
ideal body weight, cisatracurium 100 mg/kg of ideal weight. Maintainance with desflurane and fentanyl 100 µg
boluses every 40 minutes. Thirty minutes before end of surgery: metoclopramide 10 mg, and ketorolac 1 mg/kg
ideal weight
◦ After surgery: Within 12 hours after surgery, ketorolac or any other pain killer was administered as part of
the postoperative protocol recommended by Calvin W. Lee et al
Outcomes VAS pain 0 to 10 at 1 and 12 hours after surgery (converted by study authors post hoc to a dichotomous value: VAS
0 to 5 = no pain, and VAS 5 to 10 = pain)
Ramsay Sedation Scale at emersion and at 1 hour after surgery
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Ceballos 2011 (Continued)
Notes Baseline imbalance regarding gender: men/women in dexmedetomidine group vs fentanyl group, respectively, 32/13
and 14/32
Need for fentanyl was different between groups: dexmedetomidine group required a mean (± SD) of 3.7 (± 0.99)
µg/kg/h, whereas fentanyl group required 5.5 (± 0.68) µg/kg/h
Study authors contacted for details on amount and type of rescue analgesia, and for not-dichotomized VAS pain
scores, without reply
Kilicaslan 2006
Methods RCT, 2 parallel groups
Participants Number: 25 participants
Country: Turkey
Surgery: elective lower abdominal surgery (including gynaecology)
Age: adults
ASA: I to II
Other inclusion criteria: not stated
Exclusion criteria: not stated
Interventions • Dexmedetomidine 1 µg/kg as an intravenous bolus preoperatively
vs
• Normal saline solution infused preoperatively, identical volume
Outcomes Haemodynamics preoperatively, perioperatively and postoperatively
Desflurane requirements
Catecholamine levels
Sedation, pain and recovery scores postoperatively
Notes Study authors contacted for individual information on participants undergoing abdominal and not gynaecological
operations, but no reply
Kordan 2006
Methods RCT, 3 parallel groups
Participants Number: 45 participants
Country: Turkey
Surgery: not stated
Age: not stated
ASA: not stated
Other inclusion criteria: not stated
Exclusion criteria: not stated
Interventions • Dexmedetomidine 0.6 µg/kg as intravenous bolus over 1 minute before induction of anaesthesia
vs
• Dexmedetomidne 1 µg/kg intravenous bolus over 5 minutes before induction of anaesthesia
vs
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Kordan 2006 (Continued)
• Dexmedetomidine 2 µg/kg intravenous bolus over 10 minutes before induction of anaesthesia
Outcomes Haemodynamics perioperatively and postoperatively
Anaesthetic requirements
Sedation scores postoperatively
Recovery score
Side effects
Notes We were unable to locate anything but an abstract. Study authors would have been contacted to specify outcomes
and type of surgery if we could have found an address
Mizrak 2010
Methods RCT, 2 parallel groups
Participants Number: 90 participants
Country: Turkey
Surgery: 24 inguinal hernia, 32 laparoscopic cholecystectomy, 34 breast biopsy under general anaesthesia
Age: 18 to 60 years
ASA: I to II
Inclusion criteria: none stated
Exclusion criteria: heart blocks, heart failure, hepatic failure, psychiatric disease, neurological disease, drug allergy,
analgesics or sedatives within previous 24 hours
Interventions • Dexmedetomidine 0.5 µg/kg intravenous bolus before induction of anaesthesia
vs
• Thiopental 1 mg/kg intravenous bolus before induction of anaesthesia
vs
• Normal saline
Outcomes Recovery time
VAS postoperative pain
Side effects including headache, nausea, vomiting, coughing and fever
Notes Study authors contacted for individual participant data for abdominal surgery. No reply
Scheinin 1992
Methods RCT, 2 parallel groups
Participants Number: 24 men (n = 11) and women (n = 13)
Country: Finland
Surgery: laparotomy, breast surgery, anal surgery, various surgery
Age: adults
ASA: I
Other inclusion criteria: none stated
Exclusion criteria: use of any medication, childbearing potential, known allergy
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Scheinin 1992 (Continued)
Interventions • Dexmedetomidine 0.6 µg/kg intravenous bolus over 10 minutes before induction of anaesthesia
vs
• Saline, identical volume and timing
Outcomes Analgesic requirements during the first 2 hours postoperatively
Notes Study authors contacted to obtain specific data for abdominal surgery, but no reply (study from 1992)
Subasi 2012
Methods RCT, 2 parallel groups
Participants Number: 40 participants
Country: Turkey
Surgery: laparoscopic cholecystectomy
Age: 18 to 60 years
ASA: I to II
Other inclusion criteria: none stated
Exclusion criteria: not stated
Interventions • Dexmedetomidine started at 0.5 µg/kg/h intravenous infusion and reduced to 0.3 µg/kg/h at 5 minutes after
incision
vs
• Remifentanil started at 0.5 mg/kg/min intravenous infusion and reduced to 0.3 mg/kg/min 5 minutes after
incision
All participants:
◦ During surgery: Propofol 2.5 mg/kg and 150 µg/kg/min, rocuronium 0.6 mg/kg, fentanyl 1 µg/kg
Outcomes Time to recovery
Postoperative analgesic requirements
Postoperative haemodynamic parameters
Postoperative pain scores
Time to first analgesic need
Notes Only conference abstract available. Study authors contacted to obtain more information, but no reply
Unlugenc 2005
Methods RCT, 2 parallel groups
Participants Number: 60 men (n = 21) and women (n = 39)
Country: Turkey
Surgery: mini-laparotomy (3), cholecystectomy (30), splenectomy (4), inguinal, incisional or umbilical hernia repair
(23)
Age: 18 to 64 years
ASA: I to II
Other inclusion criteria: none reported
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Unlugenc 2005 (Continued)
Exclusion criteria: inability to use the PCA device, long-term use of opioids and history of chronic pain
Interventions • Dexmedetomidine 1 µg/kg intravenous bolus over 10 minutes before induction of anaesthesia (n = 30)
vs
• Saline 0.9% administered in the same way (n = 30)
All participants:
◦ Premedication: none other than dexmedetomidine
◦ Anaesthesia and during surgery: thiopental (3 to 5 mg/kg), sevoflurane 1% to 2% in nitrous oxide/oxygen
2:1. Vecuronium bromide 0.1 to 0.2 mg/kg and 0.03 mg/kg at 30-minute intervals. Intravenous morphine 0.1 mg/
kg 20 minutes before end of surgery. Neostigmine (0.05 mg/ kg) and atropine (0.015 mg/kg)
◦ After surgery: PCA morphine with 0.02 mg/kg boluses. Ondansetron 4 mg and meperidine 0.4 mg/kg
intravenously, repeated if necessary every 4 hours. The PCA pump was removed 24 hours after surgery, and
intravenous dipyrone (metamizole), 3 g per day, was prescribed for pain management
Outcomes The following outcomes measured at 2, 6, 12 and 24 hours after start of PCA morphine:
• VRS pain at rest 0 to 10
• Amount of PCA morphine
• Sedation score (5-point scale with 1 = alert and 5 = deep sleep)
• Nausea score (5-point scale with 1: none and 5: constant and severe), but not number of participants with
PONV
• Any side effects
Notes Study authors contacted for individual participant data, because this review does not include hernia repair. No reply
Yacout 2012
Methods RCT, 2 parallel groups
Participants Number: 30 men (n = 17) and women (n = 13)
Country: Egypt
Surgery: major abdominal surgery (not specified which type or if laparoscopic/open), elective, general anaesthesia
Age: range not reported, mean age in dexmedetomidine group 49.6 and in placebo group 47.1 years
ASA: I to III
Other inclusion criteria: none mentioned
Exclusion criteria: none mentioned
Interventions • Dexmedetomidine 1 µg/kg intravenous bolus over 10 minutes before induction of anaesthesia, then 0.5 µg/
kg/hr infusion until end of surgery (n = 15)
vs
• Normal saline administered in the same way (n = 15)
All participants:
◦ Premedication: nothing reported
◦ Anaesthesia and during surgery: thoracic epidural catheter before induction of anaesthesia and “all patients
received the same anaesthetic technique” (nothing else reported)
◦ After surgery: nothing reported
Outcomes VAS pain at 6, 12 and 24 hours postoperatively
Amount of ketorolac during 24 hours postoperatively
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Yacout 2012 (Continued)
Notes This study reported no standard deviations or other variation for results, but found a ’significant difference’ with a
mean dose of ketorolac 24 hours after surgery at 3.8 mg in the dexmedetomidine group vs 16.0 mg in the placebo
group. No opioids were used. VAS postoperative pain was with ’no significant difference’ between groups at 6, 12 and
24 hours after surgery (only during the first postoperative hour, a significant difference in favour of dexmedetomidine
was found). The study reported no side effects
We tried to contact study authors for information about standard deviations, type of abdominal surgery, etc, but
with no response
Yektas 2011
Methods RCT, 9 parallel groups
Participants Number: 180 participants (9 × 20)
Country: Turkey
Surgery: inguinal surgery
Age: 20 to 30 years
ASA: I
Other inclusion criteria: spinal anaesthesia
Exclusion criteria: drug abuse, recall of pain at earlier surgery, need for additional sedation at earlier surgery,
cerebrospinal fluid could not be obtained after 3 attempts, education level below primary school
Interventions Control group: 15 mg hyperbaric bupivacaine and 0.5 mL physiological serum intrathecally
vs
In the other groups, serum was replaced with the following to a total volume of 3.5 mL:
• Hyperbaric bupivacaine 2.5 mg
vs
• Ketamine 12.5 mg
vs
• Fentanyl 25 µg
vs
• Sufentanil 2.5 µg
vs
• Dexmedetomidine 2 µg
vs
• Neostigmine 250 µg
vs
• Midazolam 500 µg
vs
• Droperidole 1.25 mg
Outcomes Intraoperative and postoperative side effects
Time to first pain
Notes Only abstract of conference paper available. Study authors contacted for additional information, awaiting reply
RCT: randomized controlled trial; ASA: American Society of Anesthesiologists Physical Status 1 to 6, where 1 = Healthy person, 2 =
Mild systemic disease, 3 = Severe systemic disease, 4 = Severe systemic disease that is a constant threat to life, 5 = A moribund person
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who is not expected to survive without the operation, 6 = A declared brain-dead person whose organs are being removed for donor
purposes; PCA: patient-controlled analgesia; PACU: post-anaesthesia care unit; BMI: body mass index
Characteristics of ongoing studies [ordered by study ID]
Awad 2014
Trial name or title Intravenous Dexmedetomidine for the Prevention of Postoperative Shivering in Patients Undergoing General
Anaesthesia
Methods RCT, 4 parallel groups
Participants Number: 216 participants, both genders
Country: Lebanon
Surgery: elective surgery under general anaesthesia with estimated time of 1 to 3 hours - type not stated
Age: 18 to 80 years
ASA: I to III
Other inclusion criteria: none stated
Exclusion criteria: duration of surgery < 1 hour or > 3 hours; allergy to dexmedetomidine, vasoactive
antidepressant or analgesics; BMI > 30 kg/m2, fever, pregnancy
Interventions • Dexmedetomidine 0.25 µg/kg intravenous bolus over 10 minutes at end of administration of
sevoflurane
vs
• Dexmedetomidine 0.5 µg/kg intravenous bolus over 10 minutes at end of administration of sevoflurane
vs
• Dexmedetomidine 1 µg/kg IV intravenous bolus over 10 minutes at end of administration of
sevoflurane
vs
• Normal saline administered at same volume and timing
Outcomes Time to extubation, awakening and orientation
Sedation scores up to 1 hour postoperatively
Pain scores up to 1 hour postoperatively
Nausea and vomiting up to 1 hour postoperatively
Starting date May 2014
Contact information Dr. Marie Awad, Professor of Clinical Specialty, American University of Beirut Medical Center
mm01@aub.edu.lb
Notes Study authors contacted to obtain data on type of surgery, but no reply
Status at clinicaltrials.gov: recruiting, last verified May 2014
Clinical Trials identifier: NCT02141412
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Jung 2014
Trial name or title Effect of Dexmedetomidine on Recovery Profiles of Elderly Patients
Methods RCT, 4 parallel groups
Participants Number: 120 participants, both genders
Country: Korea
Surgery: not stated, elective
Age: > 65 years
ASA: I to II
Other inclusion criteria: not stated
Exclusion criteria: severe heart disease (New York Heart Association class > III, severe arrhythmia, uncon-
trolled hypertension or hypotension, hypersensitivity to drugs, cognitive deficiency, dementia or delirium,
hepatic or renal impairment, infective disease
Interventions • General anaesthesia with sevoflurane (n = 30)
vs
• General anaesthesia with propofol and remifentanil (n = 30)
vs
• General anaesthesia with sevoflurane. Infusion of dexmedetomidine (0.4 µg/kg/h) during anaesthesia
(n = 30)
vs
• General anaesthesia with propofol and remifentanil. Infusion of dexmedetomidine (0.4 µg/kg/h)
during surgery (n = 30)
Outcomes Recovery characteristics (time to recovery of consciousness (ROC) and recovery)
Bispectral index (BIS) values at ROC and orientation
Ricker sedation-agitated scale at the postanaesthetic care unit
Safety (vital signs during and after administration of dexmedetomidine)
Starting date May 2013
Contact information Study Chair: Ki Tae Jung, MD, Department of Anesthesiology and Pain Medicine, School of Medicine,
Chosun University, Gwangju, Korea, 501-717
Notes Status at clinicaltrials.gov: completed, last verified March 2014, no results posted
Clinical Trials identifier: NCT01851005
Type of surgery not stated - might not be abdominal surgery
Kim 2014
Trial name or title The Effect of Dexmedetomidine on Postoperative Analgesia
Methods RCT, 2 parallel groups
Participants Number: 95 participants, both genders
Country: Korea
Surgery: elective surgery for colon cancer
Age: 20 to 74 years
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Kim 2014 (Continued)
ASA: not stated
Other inclusion criteria: none stated
Exclusion criteria: hepatic or renal disease, allergy to study drugs, inability to use patient-controlled analgesia
Interventions • Dexmedetomidine 500 µg plus fentanyl 2500 µg plus saline 45 mL
vs
• Fentanyl 2500 µg + saline 50 mL
Outcomes Total amount of administered fentanyl during first 24 hours after surgery
Starting date June 2011
Contact information Study Chair: Yong Chul Kim, Professor
Seoul National University Hospital, Seoul, Korea, 110-744
Notes Details of drug administration or timing not available
Status at clinicaltrials.gov: completed, last verified March 2012, no results posted
Clinical Trials identifier: NCT01373021
Wai 2014
Trial name or title Multimodal Analgesic Using Morphine and COX-2 With or Without Dexmedetomidine for Colorectal
Surgery
Methods RCT, 2 parallel groups
Participants Number: 100 participants, both genders
Country: Hong Kong
Surgery: colorectal
Age: 18 to 80 years
ASA: I to III
Other inclusion criteria: none stated
Exclusion criteria: extended resection involving other organs such as liver and urinary bladder; allergy to
alpha-2 agonists, opioids, non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors or
sulphonamides; regular use of clonidine, methyldopa, opioids or psychiatric drugs; alcohol or drug abuse;
second- or third-degree heart block; ischaemic heart disease, valvular heart disease or heart failure; history of
pulmonary embolism or deep vein thrombosis; sleep apnoea; impaired renal function, defined as preoperative
serum creatinine level over 120 µmol/L; impaired hepatic function, defined as preoperative serum albumin
level < 30 g/L; impaired or retarded mental state; not self ambulatory before operation; difficulties in using
patient-controlled analgesia; BMI > 35 kg/m2; pregnancy; patient refusal
Interventions • Dexmedetomidine 1 µg/kg intravenous bolus over 10 minutes before induction, followed by
continuous infusion 0.5 µg/kg/h until wound closure (n = 50)
vs
• Normal saline at same volume and rate (n = 50)
Outcomes Postoperative pain score on numerical rating scale during 5 days
Number of participants with flatus during 5 days
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Wai 2014 (Continued)
Starting date May 2008
Contact information Cheung Chi Wai, Clinical Associate Professor, The University of Hong Kong; nothing else stated
Notes Status at clinicaltrials.gov: completed, last verified April 2013, no results posted
Clinical Trials identifier: NCT01353456
Yoo 2014
Trial name or title The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients
Undergoing Laparoscopic Gastrectomy
Methods RCT, 2 parallel groups
Participants Number: 92 participants, both genders
Country: Korea
Surgery: elective laparoscopic gastrectomy
Age: 20 to 65 years
ASA: I to III
Other inclusion criteria: gastric cancer
Exclusion criteria: ASA physical status , bradycardia (< 60 beats/min), arrhythmia, uncompensated heart
failure, hepatic failure, renal failure
Interventions • Dexmedetomidine infusion from induction of anaesthesia to end of surgery (n = 46)
vs
• Saline infusion from induction of anaesthesia to end of surgery (n = 46)
Outcomes Time to first gas passing
Time to intake of sips of water
Time to intake of soft diet
Starting date June 2014
Contact information Young Chul Yoo, MD, Department of Anesthesiology and Pain Medicine, Yonsei University College of
Medicine, Seoul, Korea, Republic of, 120-752, seaoyster@yuhs.ac
Notes Status at clinicaltrials.gov: recruiting patients, last verified June 2014
Clinical Trials identifier: NCT02164448
Zeeni 2014
Trial name or title Dexmedetomidine for Postoperative Analgesia After Bariatric Surgery
Methods RCT, 2 parallel groups
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Zeeni 2014 (Continued)
Participants Number: 60 participants, both genders
Country: Lebanon
Surgery: laparoscopic sleeve gastrectomy bariatric surgery
Age: 18 to 70 years
ASA: I to II
Other inclusion criteria: body mass index > 40 kg/m2 or > 35 kg/m2 with co-morbidity such as hypertension,
diabetes or sleep apnoea
Exclusion criteria: allergy to opioids or alpha-2 agonists; weight > 180 kg; uncontrolled hypertension; heart
block greater than first degree; prolonged QT interval; clinically significant neurological, cardiovascular, renal,
hepatic or gastrointestinal disease; opioid analgesic medication within 24 hours; history of alcohol, drug abuse
or long-term opioid intake or psychiatric disorder; pregnancy or breast-feeding
Interventions • Dexmedetomidine 1 µg/kg intravenous bolus over 10 minutes before anticipated end of surgery,
followed by 0.5 µg/kg/h infusion until removal of laparoscopes (n = 30)
vs
• Morphine 0.08 mg/kg intravenous bolus over 10 minutes followed by saline infusion until removal of
laparoscopes (n = 30)
Outcomes Total dose of morphine consumed in PACU
Time to first morphine requirement in PACU
Numerical rating scale (NRS) for pain
NRS for nausea
Incidence of pruritus
Incidence of vomiting or retching
Incidence of respiratory complications
Time to discharge readiness in PACU
Total morphine consumption at 24 hours
Quality of recovery (QoR-40) score at 24 hours
Overall satisfaction at 1 month
Starting date August 2014
Contact information American University of Beirut Medical Center, Beirut, Lebanon
Contact: Carine Zeeni, MD, 961 1 350000 ext 6380, cz07@aub.edu.lb
Contact: Sahar Siddik, MD, 961 1 350000 ext 6380, ss01@aub.edu.lb
Notes Status at clinicaltrials.gov: recruiting patients, last verified July 2014
Clinical Trials identifier: NCT02213159
RCT: randomized controlled trial; ASA: American Society of Anesthesiologists Physical Status 1 to 6, where 1 = Healthy person, 2 =
Mild systemic disease, 3 = Severe systemic disease, 4 = Severe systemic disease that is a constant threat to life, 5 = A moribund person
who is not expected to survive without the operation, 6 = A declared brain-dead person whose organs are being removed for donor
purposes; BMI: body mass index
63Perioperative dexmedetomidine for acute pain after abdominal surgery in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Dexmedetomidine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Amount of ’rescue’ opioid 3
hours after surgery (intravenous
morphine equivalents)
2 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Amount of ’rescue’ opioid 24
hours after surgery (intravenous
morphine equivalents)
4 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Postoperative pain 3 hours after
surgery (VAS 0-100)
2 Mean Difference (IV, Random, 95% CI) Totals not selected
4 Postoperative pain 6 hours after
surgery (VAS 0-100)
2 Mean Difference (IV, Random, 95% CI) Totals not selected
5 Postoperative pain 12 hours after
surgery (VAS 0-100)
2 Mean Difference (IV, Random, 95% CI) Totals not selected
6 Postoperative pain 24 hours after
surgery (VAS 0-100)
4 Mean Difference (IV, Random, 95% CI) Totals not selected
7 Postoperative nausea and
vomiting (PONV)
3 Risk Ratio (IV, Random, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Dexmedetomidine versus placebo, Outcome 1 Amount of ’rescue’ opioid 3
hours after surgery (intravenous morphine equivalents).
Review: Perioperative dexmedetomidine for acute pain after abdominal surgery in adults
Comparison: 1 Dexmedetomidine versus placebo
Outcome: 1 Amount of ’rescue’ opioid 3 hours after surgery (intravenous morphine equivalents)
Study or subgroup Dexmedetomidine Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[mg] N Mean(SD)[mg] IV,Random,95% CI IV,Random,95% CI
Bakhamees 2007 (1) 40 5 (1.4) 40 10.2 (1.3) -5.20 [ -5.79, -4.61 ]
Tufanogullari 2008 (2) 57 5.7 (3.9) 20 9.35 (4.95) -3.65 [ -6.04, -1.26 ]
-100 -50 0 50 100
Favours dexmedetomidine Favours placebo
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(1) Data from 2 hours after surgery
(2) Time point was initial time in PACU with personnel-administered fentanyl, until PCA morphine possible
Analysis 1.2. Comparison 1 Dexmedetomidine versus placebo, Outcome 2 Amount of ’rescue’ opioid 24
hours after surgery (intravenous morphine equivalents).
Review: Perioperative dexmedetomidine for acute pain after abdominal surgery in adults
Comparison: 1 Dexmedetomidine versus placebo
Outcome: 2 Amount of ’rescue’ opioid 24 hours after surgery (intravenous morphine equivalents)
Study or subgroup Dexmedetomidine Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[mg] N Mean(SD)[mg] IV,Random,95% CI IV,Random,95% CI
Bakhamees 2007 40 36 (6) 40 48 (8) -12.00 [ -15.10, -8.90 ]
Mohamed 2012 30 6.2 (0.6) 30 13.4 (0.5) -7.20 [ -7.48, -6.92 ]
Park 2012 (1) 21 1.4 (1.95) 21 1.3 (1.5) 0.10 [ -0.95, 1.15 ]
Tufanogullari 2008 (2) 57 162 (118) 20 218 (107) -56.00 [ -112.01, 0.01 ]
-100 -50 0 50 100
Favours dexmedetomidine Favours placebo
(1) Data reflected only the amount of tramadol IV given to the participants, not the difference in ketorolac between groups
(2) Time point was ”postoperative day one”, which may be several hours more than 24 hours
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Analysis 1.3. Comparison 1 Dexmedetomidine versus placebo, Outcome 3 Postoperative pain 3 hours after
surgery (VAS 0-100).
Review: Perioperative dexmedetomidine for acute pain after abdominal surgery in adults
Comparison: 1 Dexmedetomidine versus placebo
Outcome: 3 Postoperative pain 3 hours after surgery (VAS 0-100)
Study or subgroup Dexmedetomidine Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[mm] N Mean(SD)[mm] IV,Random,95% CI IV,Random,95% CI
Bakhamees 2007 (1) 40 20 (15) 40 50 (22) -30.00 [ -38.25, -21.75 ]
Mohamed 2012 (2) 30 25 (2) 30 27 (3) -2.00 [ -3.29, -0.71 ]
-100 -50 0 50 100
Favours dexmedetomidine Favours placebo
(1) Time point 2 hours after surgery, and data converted from median and interquartile range (IQR)
(2) Time points reported were two and four hours after surgery, and we have reported the mean
Analysis 1.4. Comparison 1 Dexmedetomidine versus placebo, Outcome 4 Postoperative pain 6 hours after
surgery (VAS 0-100).
Review: Perioperative dexmedetomidine for acute pain after abdominal surgery in adults
Comparison: 1 Dexmedetomidine versus placebo
Outcome: 4 Postoperative pain 6 hours after surgery (VAS 0-100)
Study or subgroup Dexmedetomidine Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[mm] N Mean(SD)[mm] IV,Random,95% CI IV,Random,95% CI
Mohamed 2012 30 24 (8) 30 27 (2) -3.00 [ -5.95, -0.05 ]
Park 2012 21 28 (11) 21 30 (18) -2.00 [ -11.02, 7.02 ]
-100 -50 0 50 100
Favours dexmedetomidine Favours placebo
66Perioperative dexmedetomidine for acute pain after abdominal surgery in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Dexmedetomidine versus placebo, Outcome 5 Postoperative pain 12 hours
after surgery (VAS 0-100).
Review: Perioperative dexmedetomidine for acute pain after abdominal surgery in adults
Comparison: 1 Dexmedetomidine versus placebo
Outcome: 5 Postoperative pain 12 hours after surgery (VAS 0-100)
Study or subgroup Dexmedetomidine Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[mm] N Mean(SD)[mm] IV,Random,95% CI IV,Random,95% CI
Mohamed 2012 30 20 (0.3) 30 26 (2) -6.00 [ -6.72, -5.28 ]
Xiao 2013 40 29 (10) 40 31 (11) -2.00 [ -6.61, 2.61 ]
-100 -50 0 50 100
Favours dexmedetomidine Favours placebo
Analysis 1.6. Comparison 1 Dexmedetomidine versus placebo, Outcome 6 Postoperative pain 24 hours
after surgery (VAS 0-100).
Review: Perioperative dexmedetomidine for acute pain after abdominal surgery in adults
Comparison: 1 Dexmedetomidine versus placebo
Outcome: 6 Postoperative pain 24 hours after surgery (VAS 0-100)
Study or subgroup Dexmedetomidine Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[mm] N Mean(SD)[mm] IV,Random,95% CI IV,Random,95% CI
Mohamed 2012 30 22 (1) 30 24 (2) -2.00 [ -2.80, -1.20 ]
Park 2012 21 25 (21) 21 32 (20) -7.00 [ -19.40, 5.40 ]
Tufanogullari 2008 57 43 (30) 20 40 (30) 3.00 [ -12.28, 18.28 ]
Xiao 2013 40 28 (9) 40 28 (9) 0.0 [ -3.94, 3.94 ]
-100 -50 0 50 100
Favours dexmedetomidine Favours placebo
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Analysis 1.7. Comparison 1 Dexmedetomidine versus placebo, Outcome 7 Postoperative nausea and
vomiting (PONV).
Review: Perioperative dexmedetomidine for acute pain after abdominal surgery in adults
Comparison: 1 Dexmedetomidine versus placebo
Outcome: 7 Postoperative nausea and vomiting (PONV)
Study or subgroup Dexmedetomidine Placebo Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Bakhamees 2007 (1) 2/40 3/40 0.67 [ 0.12, 3.78 ]
Mohamed 2012 4/30 8/30 0.50 [ 0.17, 1.48 ]
Tufanogullari 2008 20/57 13/20 0.54 [ 0.33, 0.87 ]
0.01 0.1 1 10 100
Favours dexmedetomidine Favours placebo
(1) Nausea and vomiting are reported separately for all three studies. We only report nausea
A D D I T I O N A L T A B L E S
Table 1. Studies awaiting classification from May 2015 search
Cho 2014 Perioperative infusion of lidocaine vs dexmedetomidine; effect on reduced consumption of postoperative
analgesics after laparoscopic cholecystectomy
Ibacache 2014 Effect of dexmedetomidine on postoperative glucose levels and insulin secretion in obese patients with
impaired glucose tolerance
Jun 2014 Laparoscopic appendectomy under spinal anaesthesia with dexmedetomidine infusion
Kim JM 2014 Randomized comparative study on the effects of epidural dexmedetomidine on heart rate variability during
general anaesthesia in participants undergoing gastrectomy
Le Guen 2014 Dexmedetomidine reduces propofol and remifentanil requirements during bispectral index-guided closed-
loop anaesthesia: a double-blind, placebo-controlled trial
Naja 2014 Effect of clonidine vs dexmedetomidine on pain control after laparoscopic gastric sleeve: a prospective,
randomized, double-blinded study
Singh 2014 Effect of dexmedetomidine on haemodynamics, fentanyl requirement and recovery profile in patients with
laparoscopic cholecystectomy
Wang 2015 Effects of dexmedetomidine on patients undergoing radical gastrectomy
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Table 1. Studies awaiting classification from May 2015 search (Continued)
Ziemann-Gimmel 2014 Opioid-free total intravenous anaesthesia reduces postoperative nausea and vomiting in bariatric surgery
beyond triple prophylaxis
We reran the search in May 2015. These potential new studies of interest published between May 2014 and May 2015 will be
incorporated into formal review findings during the review update
Table 2. Baseline data and overview of characteristics of included studies
Study (n)
, country
Groups
(n)
Route
and
mode of
adminis-
tration
Participants Type (n)
and du-
ration of
surgery
(min-
utes)
’Rescue’
analgesia
Other
relevant
medica-
tion
1.
Premedi-
cation
2.
During
surgery
age
(years)
weight
(kg)
height
(cm)
gender
M/F (n)
ASA (n)
Bakhamees
2007 (80)
Egypt
DEX (40) Intra-
venous
bolus (0.
8 µg/kg)
plus infu-
sion (0.4
µg/kg/h)
30 ± 6 123 ± 27 169 ± 10 16/14c II: 26
III: 14
Laparo-
scopic
gastric
bypass
157 ± 29
PCA
mor-
phine
1.
Dexam-
ethazone
8 mg, mi-
dazolam
3 mg
2. Propo-
fol 1447
± 310mg,
fentanyl
199.4 ±
44.6 µg
Placebo
(40)
Same vol-
ume and
rate
29 ± 8 119 ± 21 168 ± 8 18/12c II: 24
III: 16
Laparo-
scopic
gastric
bypass
155 ± 27
PCA
mor-
phine
1.
Dexam-
ethazone
8 mg, mi-
dazolam
3 mg
2. Propo-
fol 2162
± 454mg,
fentanyl
362.2 ±
57.2 µg
Feld 2006
(20)
USA
DEX (10) Intra-
venous
40 ± 8 175 ± 49a 152 ± 13a 4/6 II: 6
III: 4
Open
gastric
PCA
mor-
1. Mida-
zolam 2
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Table 2. Baseline data and overview of characteristics of included studies (Continued)
bolus (0.
5 µg/kg)
plus infu-
sion (0.4
µg/kg/h)
bypass
234 ± 28
phine mg
2.
Thiopen-
tal 2.1 ±
0.
5 mg/kg,
less des-
flurane
than con-
trol group
Fentanyl
(10)
Intra-
venous
bolus (0.
5 µg/kg)
plus infu-
sion (0.5
µg/kg/h)
39 ± 6 159 ± 27a 152 ± 8a 3/7 II: 6
III: 4
Open
gastric
bypass
229 ± 30
PCA
mor-
phine
1. Mida-
zolam 2
mg
2.
Thiopen-
tal 3.1 ±
0.
6 mg/kg,
more des-
flu-
rane than
DEX
group
Khanduja
2013 (60)
India
DEX (30) Intra-
venous
infu-
sion (ini-
tiated at
0.5
and aug-
mented
to 0.6µg/
kg/h)
42.2 ±12.
1
57 ± 7.03 NR 6/24 I-II?d Laparo-
scopic
cholecys-
tectomy
NR
Penta-
zocineh
1. Es-
omepra-
zole 40
mg
2. End-
inspira-
tory
isoflurane
0.
6%, pen-
tazocine
17.9 ± 4.
13 mgk
Placebo
(30)
Same vol-
ume and
rate
40.4 ±11.
1
56.6 ± 7.
45
NR 6/24 I-II? Laparo-
scopic
cholecys-
tectomy
NR
Penta-
zocine
1. Es-
omepra-
zole 40
mg
2. End-
inspira-
tory
isoflurane
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Table 2. Baseline data and overview of characteristics of included studies (Continued)
1.
2%, pen-
tazocine
29.4 ± 4.
27 mg
Mo-
hamed
2012 (90)
Egypt
DEX (30) Intrathe-
cal
bolus
dexmedeto-
midine 5
µg plus
bupiva-
caine 0.
5% 10
mg
45 ± 2 72.8±1.7 164 ± 1,5 12/18 I: 27e
II: 3
Major ab-
dominal
cancerg
188 ± 53
IV tra-
madol if
VAS pain
≥ 3
1.
Oral di-
azepam 5
mg
2. Anaes-
thesia not
described
DEX
+ fentanyl
(30)b
Intrathe-
cal
bolus
dexmedeto-
midine 5
µg plus
fentanyl
25 µg
plus
bupiva-
caine 0.
5% 10
mg
44 ± 2 73.0±1.7 163 ± 1.4 8/22 I: 25
II: 5
Major ab-
dominal
cancer
190 ± 62
Same as
above
Same as
above
Placebo
(30)
Intrathe-
cal
bolus
of bupi-
vacaine 0.
5% 10
mg
44 ± 2 72.8±0.7 163.7±1.
3
10/20 I: 26
II: 4
Major ab-
dominal
cancer
173 ± 62
Same as
above
1.
Oral di-
azepam 5
mg
2. Anaes-
thesia not
described
Park
2012 (42)
Korea
DEX (21) Intra-
venous
bolus (1.
0 µg/kg)
plus infu-
sion (0.5
µg/kg/h)
42 ± 10 63.1±11.
6
164.2±6.
4
9/12 I:15f
II:5
Laparo-
scopic
cholecys-
tectomy
29 ± 11
Three-
step: IV
ketorolac,
IV
tramadol,
IV
fentanyl
at 30
minute
2. Propo-
fol 83 ±
23.4 mg,
ketorolac
30 mg IV,
dexam-
ethasone
8 mg IV,
0.25%
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Table 2. Baseline data and overview of characteristics of included studies (Continued)
in-
tervals, if
VAS pain
> 4i
bupiva-
caine
3 mL SC
and IC
Placebo
(21)
Same rate
and vol-
ume
44 ± 14 68.9±12.
1
166.5±7.
3
10/11 I: 14f
II: 6
Laparo-
scopic
cholecys-
tectomy
29 ± 14
Same as
above
Same
as above,
but
propofol
117 ± 33.
9 mg
Tu-
fanogullari
2008 (80)
USA
DEX 0.2
(20)
Intra-
venous
in-
fusion (0.
2 µg/kg/
h)
47 ± 10 127 ± 20 169 ± 10 3/17 II: 6
III: 14
Laparo-
scopic
gas-
tric band-
ing (12)/
bypass (8)
110 ± 62
Three-
step: IV
fentanyl,
PCA
mor-
phine
(2 mg bo-
lus and10
min lock-
out)
, oral hy-
dromor-
phonej
1. Mida-
zolam 20
µg/kg IV.
Cele-
coxib 400
mg orally
2. Less
desflu-
rane than
placebo
group,
bupi-
vacaine 0.
25%
at fascial
level
DEX 0.4
(20)
Intra-
venous
in-
fusion (0.
4 µg/kg/
h)
48 ± 9 138 ± 41 169 ± 8 4/16 II: 2
III: 18
Laparo-
scopic
gastric
banding
(9)/by-
pass (11)
107 ± 35
Same as
above
Same as
above
DEX 0.8
(20)
Intra-
venous
in-
fusion (0.
8 µg/kg/
h)
40 ± 10 151 ± 36 172 ± 13 9/11 II: 4
III: 16
Laparo-
scopic
gastric
banding
(9)/by-
pass (11)
111 ± 56
Same as
above
Same as
above
Placebo
(20)
Same rate
and vol-
ume
43 ± 16 127 ± 25 165 ± 12 3/17 II: 6
III: 14
Laparo-
scopic
gastric
Same as
above
Same
as above,
but more
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Table 2. Baseline data and overview of characteristics of included studies (Continued)
banding
(9)/by-
pass (11)
116 ± 52
desflu-
rane than
in DEX
groups
Xiao
2013
(120)
China
DEX plus
remifen-
tanil
high-dose
(40)
Intra-
venous
bolus
DEX (1.
0 µg/kg)
plus infu-
sion
remifen-
tanil (0.4
µg/kg/h)
57 ± 11 57 ± 10 NR 17/23 I-II Open ab-
dominal
surgery
204 ± 18
Mor-
phine
2. Less
sevoflu-
rane than
in low-
dose
remifen-
tanil
group
Placebo
plus
remifen-
tanil
high-dose
(40)
Intra-
venous
bolus
placebo
plus
infusion
remifen-
tanil (0.4
µg/kg/h)
58 ± 12 58 ± 11 NR 18/22 I-II Open ab-
dominal
surgery
198 ± 36
Mor-
phine
2. Less
sevoflu-
rane than
in low-
dose
remifen-
tanil
group
Placebo
plus
remifen-
tanil low-
doseb
(40)
Intra-
venous
bolus
placebo
plus
infusion
remifen-
tanil
(0.05 µg/
kg/h)
56 ± 13 59 ± 10 NR 18/22 I-II Open ab-
dominal
surgery
198 ± 30
Mor-
phine
2. More
sevoflu-
rane than
in other
groups
Data are reported as mean ± SD (standard deviation). ASA and gender are reported as number (n) of participants
ASA: American Society of Anesthesiologists Physical Status 1 to 6, where 1 = Healthy person, 2 = Mild systemic disease, 3 = Severe
systemic disease, 4 = Severe systemic disease that is a constant threat to life, 5 = A moribund person who is not expected to survive
without the operation, 6 = A declared brain-dead person whose organs are being removed for donor purposes; DEX: dexmedetomidine;
NR: not reported; IV: intravenous; PCA: patient-controlled analgesia; SC: subcutaneously; IC: intracutaneously
aProbably an error in height and weight; bData from this intervention arm were not included in our analysis; cError in report of gender;
dASA not reported, but probably ASA I to II; ePlease note that many participants were judged to be ASA I despite having abdominal
cancer; f Error in reporting of ASA; gNot reported if laparoscopic or open; hCriteria for administering pentazocine described only as
’an extra dose of pentazocine on complaint of immediate postoperative pain’; i In our data and analyses, we looked only at opioid, but
amount of ketorolac IV was significantly different between groups with 43.5 ± 18 mg for DEX group and 66 ± 39.6 for placebo group
(P value < 0.05). The amount of fentanyl was not reported, only that 2 participants from the placebo group needed it. Only amount of
IV tramadol was collected by us, showing no significant difference between groups. jNo other description of criteria for administering
’rescue’ analgesia. In postoperative care unit (PACU), pain was evaluated every 5 to 15 minutes, but after PACU discharge, no further
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description; kTotal dose of pentazocine was combination of intraoperative and postoperative amounts. Intraoperatively, the DEX group
received pentazocine 0.3 mg/kg, whereas the placebo group received 0.5 mg/kg, and an additional bolus of 0.1 mg/kg was administered
if signs of intraoperative pain
Table 3. Results of included studies
Comparison: dexmedetomidine versus placebo
Bakhamees
2007
Mohamed 2012 Park 2012 Tufanogullari
2008
Khanduja 2013 Xiao 2013
Number of par-
ticipants in-
cluded in this re-
view
80 60 42 77 (80)i 60 80
Outcome
’Rescue’
morphine (intra-
venous,
mg) 3 hours af-
ter surgery (MD,
95% CI)
-5.20 (-5.79, -4.
61)*a
NR NR -3.65 (-6.04, -1.
26)*b
NR NR
’Rescue’
morphine (intra-
venous,
mg) 6 hours af-
ter surgery (MD,
95% CI)
NR NR NR NR NR NR
’Rescue’
morphine (intra-
venous,
mg) 12 hours af-
ter surgery (MD,
95% CI)
NR NR NR NR NR NR
’Rescue’
morphine (intra-
venous,
mg) 24 hours af-
ter surgery (MD,
95% CI)
-12.00 (-15.10, -
8.90)*
-7.20 (-7.48, -6.
92)*
0.10 (-0.95, 1.
15)c
-56.00 (-112.01,
0.01)*f
NR NRj
VAS pain 0-100
(mm) 3 hours af-
ter surgery (MD,
95% CI)
-30.00 (-38.25, -
21.75)*d
-2.00 (-3.29, -0.
71)*e
NR NR NR NR
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Table 3. Results of included studies (Continued)
VAS pain 0-100
(mm) 6 hours af-
ter surgery (MD,
95% CI)
NR -3.00 (-5.95, -0.
05)*
-2.00 (-11.02, 7.
02)
NR NR NR
VAS pain 0-100
(mm) 12 hours
after surgery
(MD, 95% CI)
NR -6.00 (-6.72, -5.
28)*
NR NR NR -2.00 (-6.61, 2.
61)j
VAS pain 0-100
(mm) 24 hours
after surgery
(MD, 95% CI)
NR -2.00 (2.80, -1.
20)*
-7.00 (-19.40, 5.
40)
3.00 (-12.28, 18.
28)f
NR 0.00 (-3.94, 3.
94)j
Time to first re-
quest of ’rescue’
analgesia (hours,
MD, 95% CI)
NR 3.07 (2.76, 3.38)
*
NR NR NR NR
Pro-
portion of par-
ticipants need-
ing ’rescue’ anal-
gesia (RR, 95%
CI)
NR NR NR 1.00 (0.93, 1.07) 0.44 (0.15, 1.29) NR
Postoperative se-
da-
tion 12 hours af-
ter surgery (RSS,
Ramsay Seda-
tion Scale from 1
= Anxious to 6
= Unresponsive)
(MD, 95% CI)
NR NR NR NR NR 1.60 (1.49, 1.71)
†
Porportion of
participants with
PONV (RR,
95% CI)
0.67 (0.12, 3.78)
g
0.50 (0.17, 1.48)
g
NR 0.54 (0.33, 0.87)
*g
NR NR
Time to first pas-
sage of fla-
tus/stool (hours,
MD, 95% CI)
NR NR NR 5.00 (-5.60, 15.
60) h
NR NR
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Table 3. Results of included studies (Continued)
Time to first out-
of-bed mobiliza-
tion (hours,
MD, 95% CI)
NR NR NR -0.33 (-3.95, 3.
29)
NR NR
Comparison: dexmedetomidine versus fentanyl
Feld 2006
Number of par-
ticipants
20
Outcome
’Rescue’
morphine
(mg) 3 hours af-
ter surgery (MD,
95% CI)
-8.50 (-12.75, -
4.25)*
VAS pain 0-100
(mm) 3 hours af-
ter surgery (MD,
95% CI)
-40.00 (-51.53, -
28.47)*d
* Significant difference between groups in favour of dexmedetomidine (P value < 0.05)
† Significant difference between groups in favour of control (P value < 0.05)
MD: mean difference; CI: confidence interval; VAS: visual analogue scale; RR: risk ratio; PONV: postoperative nausea and vomiting;
NR: no data reported; aTime point at 2 hours after surgery; bNo specific postoperative time point reported, but only ’rescue’ opioid
(fentanyl) during initial time in PACU, given by personnel until PCA morphine possible; cThese data reflected only the amount
of intravenous tramadol given to participants, if intravenous ketorolac was not efficient. The dexmedetomidine group had smaller
consumption of ketorolac (mg) with a mean difference of -22.50 (95% CI -41.10 to -3.90). If intravenous tramadol still was not
sufficient to relieve pain, fentanyl was administered. This was necessary for 2 participants only, in the placebo group, but the dose was
not reported; dTime point 2 hours after surgery, and data converted from median and interquartile range (IQR) by presuming mean
and median to be equal, and standard deviation times 1.35 to be equal to IQR; eTime points reported were 2 and 4 hours after surgery,
and we have reported the mean; fTime point was ’postoperative day one’, which could extend some hours beyond 24 hours after
surgery; gNausea and vomiting were reported separately. We reported only nausea, presuming that participants with vomiting also had
nausea. Tufanogullari 2008 also found reduced need for ’rescue’ antiemetics at the first postoperative day (RR 0.35, 95% CI 0.20 to
0.60) together with slightly reduced intensity of nausea on a verbal rating scale (VRS) 0-10 compared with placebo during the first 30
minutes postoperatively; hOnly report of flatus, not stool; iPostoperative data from 3 participants were excluded from the final analysis,
1 from each of the 3 intervention groups (pooled to 1 intervention group in our review), because of surgical complications discovered at
the postsurgical ward. Number of participants was therefore 77 for all outcomes, except for post-interventional complications/adverse
effects, for which it was 80 (not reported in this table, but in review text); jThis trial reported amount of ’rescue’ morphine at 48 hours
after surgery only, showing a significant difference (mg, mean, SD) between the dexmedetomidine plus high-dose remifentanil group
(54 ± 13) versus the placebo plus high-dose remifentanil group (78 ± 24), with mean difference of -21.00 (95% CI -29.46 to -12.54).
Reported VAS pain scores should be interpreted with this information
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Table 4. Potential minor biases in the review process
Part of review process Description of potential minor bias
Developing the review question When choosing the proportion of participants requiring ’rescue’ analgesia as one of our secondary
outcomes, we overlooked that this outcome might not be meaningful with a design focusing
on abdominal surgery. This surgical procedure probably will for almost all participants create
some need for ’rescue’ analgesia, and hence, a difference between intervention groups regarding
this outcome could hardly be detected. After realising this, we could have chosen to exclude this
outcome, but this would make a post hoc decision after analysis of results. Had we chosen to
exclude this outcome, it would have entailed exclusion of the study by Khanduja 2013, as the
study did not report other relevant outcomes for our review
Collecting data One of our included studies was available only in Chinese (Xiao 2013), and because our review was
not funded financially, we did not purchase a professional and full translation, but only extraction
of data (see Appendix 6) performed on a voluntary basis by a medical expert in native Chinese
within The Cochrane Collaboration. Data from tables were extracted by the first and second
authors of this review, but regarding assessment of risk of bias, the study was evaluated by only
one person (the translator). However, because the study reported very little information about
randomization, allocation, blinding, etc, risk of bias introduced in the review process probably was
of minor importance. We contacted the Chinese authors for details in English, without reply
To keep focus on outcomes with importance for patients, we chose to collect data about heart
rate and blood pressure only if they required intervention. Therefore, reports of e.g. significant
differences in heart rate or bloodpressure have not been collected, unless bradycardia or hypotension
requiring intervention was reported. This decision may have led to underreporting of side effects
among studies inasmuch as one can imagine that a study reporting a significant difference in heart
rate may have omitted data about number of participants when intervention was needed
Presenting results To make the ’Summary of findings’ table as simple as possible, we decided to report only our
primary outcomes at the time point 24 hours after surgery. This decision may have represented
selective reporting and hence introduced risk of bias, inasmuch as the decision was made after
completion of data and analyses. However, all data with all time points were presented in Data
and analyses and Table 3 and were also mentioned in several sections
Assessing risk of bias Assessment of ’high risk of other bias’ for Tufanogullari 2008 can be debated (see Characteristics
of included studies). This is beyond doubt a well-conducted study with low risk of bias for all
other domains, and other reviews have assessed only the study with the highest of quality scores
(Blaudszun 2012; Schnabel 2013). We tried to contact study authors to request additional infor-
mation about the three-step ’rescue’ analgesia regimen, without success
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Dexmedetomidine] explode all trees
#2 MeSH descriptor: [Adrenergic alpha-Agonists] explode all trees
#3 (Precedex or Dexmedetomidin*) or ((adren?ergic or alpha) near agonist*)
#4 #1 or #2 or #3
#5 MeSH descriptor: [Pain, Postoperative] this term only
#6 MeSH descriptor: [Acute Pain] explode all trees
#7 MeSH descriptor: [Postoperative Period] this term only
#8 (acute near pain):ti,ab or (pain near measur*) or (recovery near (operat* or surgery)) or post?an?esthetic care unit or PACU or
(gastrointestinal near function):ti,ab or (opioid* near sparing near effect)
#9 #5 or #6 or #7 or #8
#10 #4 and #9
Appendix 2. MEDLINE search strategy (Ovid SP)
1 exp Dexmedetomidine/ or Adrenergic alpha-Agonists/ or (Precedex or Dexmedetomidin*).af. or ((adren?ergic or alpha) adj3 ago-
nist*).mp.
2 Pain, Postoperative/ or exp Acute pain/ or Postoperative Period/ or (acute adj3 pain).ti,ab. or (pain adj4 measur*).mp. or (recovery
adj3 (operat* or surgery)).mp. or post?an?esthetic care unit.mp. or PACU.mp. or (gastrointestinal adj2 function).ti,ab. or (opioid* adj2
sparing adj2 effect).mp.
3 1 and 2
4 ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or
trial.ab. or groups.ab.) not (animals not (humans and animals)).sh.
5 3 and 4
Appendix 3. EMBASE (Ovid SP) search strategy
1. exp dexmedetomidine/ or alpha adrenergic receptor stimulating agent/ or (Precedex or Dexmedetomidin*).af. or ((adren?ergic or
alpha) adj3 agonist*).mp.
2. postoperative pain/ or pain/ or postoperative period/ or (acute adj3 pain).ti,ab. or (pain adj4 measur*).mp. or (recovery adj3 (operat*
or surgery)).mp. or post?an?esthetic care unit.mp. or PACU.mp. or (gastrointestinal adj2 function).ti,ab. or (opioid* adj2 sparing adj2
effect).mp.
3. 1 and 2
4. Randomized controlled trial/ or Controlled study/ or Randomization/ or Double blind procedure/ or Single blind procedure/ or
Clinical trial/ or (clinical adj5 trial$).ti,ab,hw. or ((doubl$ or singl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).ti,ab,hw. or Placebo/
or Placebo$.ti,ab,hw. or Random$.ti,ab,hw. or Methodology.sh. or latin square.ti,ab,hw. or crossover.ti,ab,hw. or cross-over.ti,ab,hw.
or Crossover Procedure/ or Drug comparison/ or Comparative study/ or (comparative adj5 trial$).ti,ab,hw. or (control$ or prospectiv$
or volunteer$).ti,ab,hw. or exp “Evaluation and Follow Up”/ or Prospective study/
5. 3 and 4
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Appendix 4. ISI Web of Science search strategy
#1 TS=(Precedex or Dexmedetomidin*) or TS=((adren?ergic or alpha) SAME agonist*)
#2 TS=((acute SAME pain) or (pain SAME measur*) or (recovery SAME (operat* or surgery)) or post?an?esthetic care unit or PACU
or (gastrointestinal SAME function) or (opioid* adj2 sparing adj2 effect))
#3 #1 and #2
#4 TS=(random* or ((clinical or controlled) SAME trial*) or placebo* or multicenter* or prospective) or TS=((blind* or mask*) SAME
(single or double or triple or treble))
#5 #3 and #4
Appendix 5. CINAHL (EBSCOhost) search strategy
S1 ( MH “Adrenergic Alpha-Agonists”) OR ( Precedex or Dexmedetomidin* ) OR ( ((adren?ergic or alpha) N3 agonist*) )
S2 ( (MH “Postoperative Pain”) OR (MM “Acute Pain (Saba CCC)”) OR (MH “Postoperative Period”) ) OR ( (acute N3 pain) or
(pain N4 measur*) or (recovery N3 (operat* or surgery)) or post?an?esthetic care unit or PACU or (gastrointestinal N2 function) or
(opioid* adj2 sparing adj2 effect) )
S3 S1 and S2
Appendix 6. Data collection form
Instructions:
1. Where relevant, state Y = yes, N = no, UN = unclear, NR = not reported
2. Any additional information that you feel may be important should be added to the notes sections
3. All important notes should be written in the ’Important notes’
4. Add location in text every time you believe it could be important
5. You may restructure the results tables, if needed
6. Copy and paste from trial report whenever possible and when the data are important (results especially)
Review title and ID
CARG 260, Dexmedetomidine for postoperative pain in adults
Date form completed (e.g. 3 Nov 2011)
Name/ID of person extracting data
Study ID (surname of first author and year first full report of study was published e.g. Smith 2001)
Report IDs of other reports of this study (e.g. duplicate publications, follow-up studies)
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(Continued)
Report title
Reference details and report ID (including journal, authors, department, etc)
Report author contact details
Publication type (underscore)
full report
abstract
letter
other
Important notes
Data that have not yet been extracted
Questions/doubts (include location in text)
1. Study eligibility
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Type of study: randomized controlled trial, including factorial trial and cluster-randomized, but not cross-over, design (Y/N/
UN)
Participants: adults undergoing abdominal surgery, open or laparoscopic (Y/N/UN)
Type of intervention: dexmedetomidine administered perioperatively and as the sole difference between the intervention
group and the control group(s), or administered perioperatively as part of a factorial trial (Y/N/UN)
At least one of the following outcomes (underscore)
Dose of rescue opioid
Postoperative pain measured by VASa
Proportion of participants needing rescue analgesia
Time to first rescue analgesia
Postoperative sedation
Proportion of participants with nausea/vomiting or needing antiemetics
Time to first flatus/stool or proportion of participants with delay to first flatus/stool
Time to out-of-bed mobilization or proportion of participants with delay to out-of-bed mobilization
INCLUDE only if yes in all 4 categories (Y/N/UN)
EXCLUDE and record here the information to be inserted into ‘Table of excluded studies’
Notes
aVAS = visual analogue scale.
DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW
2. Characteristics of study
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Setting (underscore)
Single-centre
Multi-centre
Inclusion criteria
Exclusion criteria
Informed consent obtained
Ethical approval (underscore)
obtained
not needed
not obtained though needed
not reported
Aim of study (you may copy and paste from the ‘Objectives’ section)
Design of study (underscore)
2 parallel groups
multi-arm parallel groups
cluster-randomized
factorial trial (state 2 × 2, 2 × 3, etc)
Intervention group(s) vs control group(s) (e.g. dexmedetomidine vs morphine plus diclofenac vs placebo)
Outcomes measured (list all outcomes mentioned in the report even if no results reported)
Outcomes reported (list all outcomes when corresponding results are reported in text or in tables/figures)
In tables/figures:
In text:
Qualitatively:
Quantitatively:
Outcomes measured, but not reported:
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Total duration of study
Notes
3. Participants (provide overall data and, if available, comparative data for each intervention or comparison
group. Use group code name, e.g. ‘women D:11, M:7’)
List code names for all groups (e.g. ‘D = dexmedetomidine group, M = morphine group’)
Total number randomized, with group proportions (e.g. ‘40, 18:22’)
Baseline imbalances (describe)
Prespecified criteria for exclusion of participants after randomization
Withdrawals/exclusions and reasons why (if not described under results)
Age (describe distribution of age as reported)
Sex (numbers of men/women)
Weight and height
Country
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Other relevant sociodemographics
Description of surgical procedure(s) (and underscore elective/acute)
Elective
Acute
Description
Anaesthetic method (UA = universal anaesthesia, RA = regional anaesthesia)
Duration of surgery
American Society of Anesthesiologists (ASA) Physical Status
Other relevant treatment received (state if before, under or after surgery)
Notes
4. Subgroups
Subgroup analyses performed in paper, if any
Subgroups prespecified for review (fill in number of participants, if information available in paper)
Laparoscopic procedure Open procedure Information not available in paper (NA)
Route of administration 1 Route of administration 2 NA
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Bolus only Infusion (with or without loading dose) NA
Notes
5. Intervention groups (copy and paste this section for each intervention and comparison group)
Group name (including code)
Number randomized to group
Description (including content, dose(s), etc)
Timing (time point relative to surgery, frequency, duration of each episode)
Delivery (mechanism, medium)
Notes
6. Outcomes (copy and paste this section for each outcome)
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Outcome name
Time points when measurements were taken during the study
Time points reported in the study
Time points you are using in RevMan 5
Outcome definition
Unit of measurement
For measurement scales: state which score is best (underscore) and state name of scale with descriptions
Highest
Lowest
Name of scale
Description of steps
Notes
7. Results (copy and paste the appropriate section for each outcome, including additional tables for each time
point and subgroup as required)
7.a. Dichotomous outcome
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Comparison
Outcome
Subgroup (if relevant)
Time point (specify time point 0) (if relevant)
Intervention Number of events Number of participants Number of missing participants and reasons
Comparison Number of events Number of participants Number of missing participants and reasons
Source of data (pg., fig., table, from contact with study author)
Results calculated by you? (state formula if yes)
Results estimated from graphs? (state if yes)
Unit of analysis (state if body part and delete ’individuals’)
Individuals
Notes
7.b. Continuous outcome
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Comparison
Outcome
Subgroup (if relevant)
Time point (specify time point 0) (if relevant)
Intervention
Mean (or other measure) SD (or other variance) Number of participants Number of missing participants and reasons
Comparison
Mean (or other measure) SD (or other variance) Number of participants Number of missing participants and reasons
Source of data (pg., fig., table, from contact with study author)
Results calculated by you? (state formula if yes)
Results estimated from graphs? (state if yes)
Unit of analysis (state if body part and delete ‘individuals’)
Individuals
Notes
7.c. Other outcome
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Comparison
Outcome
Unit of measurement
Subgroup (if relevant)
Time point (specify time point 0)
Intervention
Mean (or other measure) SD (or other variance) Number of participants Number of missing participants and reasons
Comparison
Mean (or other measure) SD (or other variance) Number of participants Number of missing participants and reasons
Source of data (pg., fig., table, from contact with study author)
Results calculated by you? (state formula if yes)
Results estimated from graphs? (state if yes)
Unit of analysis (state if body part and delete ‘individuals’)
Individuals
Notes
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7.d. Outcome reported in a narrative manner
Comparison
Outcome
Subgroup (if relevant)
Results (describe)
Source of data (pg., table, from contact with study author)
Notes
8. Other information
Study funding sources/University
Possible conflicts of interest
Key conclusions of study authors (if relevant)
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References or contact details for other potentially eligible trials not already identified (published or unpublished)
Correspondence required for further study information (from whom, about what and when)
C O N T R I B U T I O N S O F A U T H O R S
Luise Jessen Lundorf (LJL), Helene Korvenius Nedergaard (HKN), Ann Merete Møller (AMM).
Conceiving of the review: LJL, AMM.
Co-ordinating the review: LJL.
Undertaking manual searches: LJL.
Screening search results: LJL.
Organizing retrieval of papers: LJL.
Screening retrieved papers against inclusion criteria: LJL, HKN.
Appraising quality of papers: LJL, HKN, AMM.
Abstracting data from papers: LJL, HKN.
Writing to authors of papers for additional information: LJL.
Providing additional data about papers: LJL, HKN.
Obtaining and screening data on unpublished studies: LJL.
Managing data for the review: LJL, HKN.
Entering data into Review Manager (RevMan 5.3): LJL, HKN.
Analysing RevMan statistical data: LJL.
Performing other statistical analyses not using RevMan: LJL.
Interpreting data: LJL, HKN, AMM.
Making statistical inferences: LJL.
Writing the review: LJL.
Securing funding for the review: LJL, AMM.
Performing previous work that was the foundation of the present study: no previous work.
Serving as guarantor for the review (one review author): AMM.
Taking responsibility for reading and checking the review before submission: LJL.
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D E C L A R A T I O N S O F I N T E R E S T
All authors: none known.
S O U R C E S O F S U P P O R T
Internal sources
• Herlev University Hospital, Denmark.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Review information
Second author Helene Korvenius Nedergaard changed her surname from Jørgensen after publication of the protocol (Jessen 2013).
Background
The Background section has been updated with references until 2014.
We have clarified that the same drug dexmedetomidine is sold as Precedex and Dexdor under two different regulatory authorities.
In our protocol, we stated both Dexdor product information and Precedex prescribing information as references for the following
sentence: “Infusion (of dexmedetomidine) exceeding 24 hours is not recommended due to the risk of agitation and respiratory
failure”. This was not correct and has now been amended to read as follows: “Infusion of dexmedetomidine exceeding 24 hours is not
recommended because of risk of agitation and respiratory failure (Precedex prescribing information); this precaution is not stated in
Dexdor product information”.
To adverse events, we have added sinus arrest, as described by Dexdor product information and Precedex prescribing information.
Types of participants
After our protocol (Jessen 2013) had been published, we narrowed our review question regarding type of surgery, from abdominal
procedures including gynaecological surgery, to only abdominal surgery. We made this decision to diminish heterogeneity in outcomes
such as postoperative pain, gastrointestinal function and mobilization, which we visualized would be difficult to pool if surgery varied
from peritoneal to vaginal procedures. The decision was made at a point when more than 30 studies seemed to meet inclusion criteria,
but before full text of studies was read and before attention was paid to study results. Therefore, the decision probably introduced
no risk of bias, although the reasons for making this decision can be discussed. We have added the following definition of abdominal
surgery to the review: “Abdominal surgery was defined as surgery to intra-abdominal organs, excluding gynaecological, urological,
vascular and superficial surgery (such as hernia repair)”.
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Types of outcome measures
In our primary outcome, we have changed ’dose’ to ’amount’.
Search methods for identification of studies
The following sentence was moved from the section Searching other resources to the section Electronic searches: “We applied no
language restrictions”.
Data extraction and management
We decided post hoc to supplement the collection of baseline data with height and weight of participants. The fact that several studies
looked at bariatric surgery influenced this decision, but because this represents baseline information and not an outcome, it probably
did not introduce risk of bias.
Assessment of heterogeneity
In the protocol, we stated: “A meta-analysis would only be appropriate ... if variation in results was not considerable (I2 statistic < 75%)
and if the amount of information was sufficient (size and number of trials)”.
In the review, we added the following clarification: “A meta-analysis would be appropriate ... only if variation in results was not
considerable, as judged by clinical and methodological measures and by the statistical measure of heterogeneity, the I2 statistic, which
ideally but not necessarily should be below 75% (Higgins 2011). Additionally, a meta-analysis would be appropriate only if the amount
of information was sufficient (size and number of trials) (Higgins 2011)”.
Assessment of risk of bias in included studies
The following paragraph has been removed: “We will judge a study as having a low risk of bias if there is low risk of bias in all
the domains. However, we will consider the likely direction and magnitude of bias. We will also take into consideration the relative
importance of different domains according to the outcome in question. We will consider a study as having a high risk of bias if there
is one or several domains with a high risk of bias. We will consider a study as having an unclear risk of bias, if there is insufficient
information in one or several domains to assess the risk of bias”. This paragraph was removed because we found it more accurate to
assess only risk of bias of outcomes and domains, not of a whole study.
We grouped outcomes in our risk of bias table post hoc, but before we looked into results of studies; therefore this probably did not
introduce any risk of bias.
Unit of analysis issues
We removed the following sentences from the section Unit of analysis issues in the protocol: “For any non-standard design, we will -
in our analysis - account for the level at which randomization occurred....For any cluster-randomized trial, we will choose one of two
methods of analysis. Depending on the number and size of the clusters, we will decide whether to perform the analysis at the same
level as the allocation (i.e. where the sample size is the number of clusters), or to perform the analysis at the level of the individual
while using a statistical method taking into account the clustering in the data”. These methodological considerations turned out to be
irrelevant because no studies applied to the problem described. These considerations will be applied in future updates of this review, if
relevant.
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Dealing with missing data
Since our protocol was published (Jessen 2013), we have added information on how we contacted study authors: “For any type of
missing data, we contacted the first author of the relevant trial to ask for additional information. If the contact information was not
directly available, we tried to retrieve an email address or a postal address by searching the Internet, or by contacting co-authors from
present or former studies. Some attempted correspondence may not have reached the addressee”.
Assessment of reporting biases
The section Assessment of reporting biases has been simplified as we were not able to create a funnel plot because the number of
included studies was too small: “If the studies are not too similar in sizes (and standard errors), we intend to conduct a test for funnel
plot asymmetry. The result will be correlated with visual interpretation of the funnel plot. For continuous outcomes with intervention
effects measured as mean differences, we intend to use the test proposed by Egger et al (Egger 1997) for funnel plot asymmetry. The
test consists in a linear regression of intervention effect estimate against its standard error, weighted by the inverse of the variance of the
intervention effect estimate. For all the other of our preferred outcome measures, a test for funnel plot asymmetry is not recommended
(Higgins 2011). Hence, any asymmetry will be ascribed by visual interpretation alone. In the case of funnel plot asymmetry, publication
bias is only one of several possible explanations. Poor methodological quality in smaller studies is another common explanation. We
will seek to understand the most probable source of the asymmetry and perform sensitivity analyses accordingly”. If future updates of
this review make funnel plots possible, we plan to do as described.
Data synthesis
The section Data synthesis has been shortened as we did not perform meta-analyses because data were few and heterogeneity across
studies was considerable. In the protocol, we stated: “As mentioned in the Assessment of heterogeneity section, we plan to perform
a meta-analysis if heterogeneity is not considerable. At the same time, we expect a certain amount of variation between studies. The
effect of dexmedetomidine on the outcomes selected is likely to vary with different types of participants (types of surgery, types of
comorbidity), and with different types of intervention (variation in administration, dosage and duration). Consequently, we plan to
perform a random-effects meta-analysis. For all selected outcomes (except post-interventional complications or adverse effects), we
intend to use a variant of the inverse variance meta-analysis method, the DerSimonian and Laird method (DerSimonian 1986), in
which the standard errors are adjusted to the estimated variation among intervention effects. As a sensitivity analysis, we intend to
perform a fixed-effect meta-analysis. In this context, we will choose the Mantel-Haenszel method (Greenland 1985; Mantel 1959)
for dichotomous outcomes when number of participants or studies is small. Among our selected outcomes, we do not expect post-
interventional complications and adverse effects to be suitable for a meta-analysis or for the Summary of findings table. Instead, we
intend to make a narrative report”. If future updates of this review make meta-analyses appropriate, we plan to do as described.
Subgroup analysis and investigation of heterogeneity
In the section Subgroup analysis and investigation of heterogeneity, we stated the following in the protocol (Jessen 2013).
“In order to investigate heterogeneity, we plan to undertake the following subgroup analyses, if required:
• laparoscopic procedures versus open procedures;
• gynaecological surgery versus other types of abdominal surgery;
• single-dose versus infusion (with or without loading dose); and
• route of administration”.
If future updates of this review make subgroup analyses possible, we plan to do as described. However, we will not perform the subgroup
analysis of gynaecological surgery versus other types of abdominal surgery for the reasons stated under Types of participants in this
section.
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Sensitivity analysis
In the section Sensitivity analysis, we stated the following in the protocol.
“In order to clarify if any findings of our meta-analyses are robust to the arbitrary decisions made during the review process, we intend
to perform several sensitivity analyses as appropriate given the data available:
• exclusion of studies at high risk of bias, as well as exclusion of studies at high and unclear risk of bias;
• change in measures of intervention effect (e.g. from RR to odds ratio, from MD to SMD, if possible), in the case of substantial
heterogeneity;
• comparison of random-effects with fixed-effect meta-analysis. This sensitivity analysis will help to clarify the reasons for any
asymmetry in funnel plots. If the random-effects model results in more beneficial intervention effects, it will indicate small-study
effects (arising from publication bias or from poor methodological quality or both) and not just artefact, true heterogeneity or chance
as the cause of asymmetry. In this case, we will consider excluding smaller studies in another sensitivity analysis; and
• trim-and-fill method to identify and correct publication bias expressed as funnel plot asymmetry”.
If future updates of this review make sensitivity analyses possible, we plan to do as described.
Summary of findings
As no meta-analyses were performed, we did not make use of the GRADE software available for assessing quality of evidence, as specified
in the protocol.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Abdomen [∗surgery]; Acute Pain [∗drug therapy]; Analgesics, Non-Narcotic [adverse effects; ∗therapeutic use]; Analgesics, Opioid
[administration & dosage]; Dexmedetomidine [adverse effects; ∗therapeutic use]; Fentanyl [therapeutic use]; Pain Measurement; Pain,
Postoperative [∗drug therapy]
MeSH check words
Adult; Humans; Middle Aged
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